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Abbreviation 
 
PCTK3              PCTAIRE kinase 3…………………………………………............. 
CDK                cyclin dependent kinase…………………………………………..... 
Rb                  retinoblastoma protein…………………………………………....... 
PKA                cAMP-dependent kinase…  …………………………..………... 
FAK                focal adhesion kinase… ……………………………………..... . 
ECM                extracellular matrix…………………………………………............ 
GAP                GTPase-activating protein…………………… …………………… 
GEF                 guanine nucleotide exchanging factor ……… …………………… 
GDI                 guanine nucleotide dissociation inhibitors………………………… 
ROCK               rho-associated kinase…………………………………………........ 
MLC                myosin light chain…………………………………………............. 
LIMK               LIM-domain kinase…………………………………………............ 
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Chapter 1. Abstract 
PCTAIRE kinase 3/cyclin dependent kinase 18 (PCTK3/CDK18) is a member of serine/threonine 
protein kinase that belongs to the cyclin dependent kinase (CDK) family. The CDK family controls 
various cellular functions, such as cell proliferation, differentiation, and motility. However, the 
physiological function of PCTK3 has been unknown because of unidentified activator(s). In this study, 
I revealed the activation mechanism of PCTK3, and which is involved in the regulation of actin 
cytoskeleton. First, I identified cyclin A2 and cyclin E1 as interacting proteins of PCTK3. The PCTK3 
activity toward retinoblastoma protein (Rb) was increased by cyclin A2, while cyclin E1 did not 
activate PCTK3. I also found that cytoplasmic cyclin A2 stability was increased in the presence of 
PCTK3. Furthermore, PCTK3 contains some putative PKA phosphorylation sites. In vivo and In vitro 
kinase assay revealed that PKA directly phosphorylated PCTK3 at Ser12, Ser66, and Ser109. The activity 
of phosphomimic PCTK3 S12D mutant was significantly increased even in the absence of cyclin A2, 
and which was comparative to that of CDK2/cyclin A2 complex in the presence of cyclin A2. Next, I 
examined the physiological function of PCTK3 using RNA interference. PCTK3-knockdown in 
HEK293T cells induced morphological change and polymerized actin accumulation in the leading 
edge. Additionally, I demonstrated that phosphorylation of cofilin, an actin depolymerizing factor, was 
increased in PCTK3-knockdown cells. Because cofilin depolymerizing activity is regulated by Rho 
GTPases such as RhoA and Rac1, I investigated whether PCTK3 affects the activities of RhoA and 
Rac1. PCTK3 knockdown led to RhoA activation and Rac1 inactivation in HEK293T cells, indicating 
that PCTK3 modulates actin cytoskeleton via the regulation of RhoGTPase activity. Finally, I found 
that PCTK3 knockdown also promoted the activation of focal adhesion kinase (FAK), suggesting that 
PCTK3 might act as a negative regulator of FAK. Taken together, my results provide the evidence that 
PCTK3 activity is regulated by cyclin A2 and PKA in the cytoplasm, and that PCTK3 controls actin 
dynamics through negatively modulating the RhoA and FAK activities. 
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Chapter 2. General Introduction 
2.1. PCTAIER Kinase 3/Cyclin-Dependent Kinase 18  
In mammal, cyclin dependent kinases (CDKs), a family of serine/threonine protein kinase, play 
an important role in the regulation of cellular functions such as cell proliferation, transcription and 
neural function [1]. Their activities are regulated by association with different cyclins and 
phosphorylation at specific sites by protein kinases [2]. Since cyclins are differentially expressed and 
degraded by ubiquitin mediated proteolysis at specific phase of cell cycle, the CDK activity is 
oscillated during the cell cycle transition [3]. Canonical CDKs contain the PSTAIRE helix implicated 
in binding to cyclins in the kinase domain [1]. The PCTAIRE kinase (PCTK) subfamily of the CDK 
family consists of three members, PCTK1/CDK16, PCTK2/CDK17 and PCTK3/CDK18, and contains 
the PCTAIRE sequence instead of the PSTAIRE sequence. PCTK family members show high 
sequence homology in their central kinase domain, while the structures of their N-terminal and 
C-terminal regions are different from each other. The PCTK genes are conserved in higher eukaryotes 
from Caenorhabditis elegans to human, but there are no PCTK orthologous in the yeast. The PCTK 
subfamily is widely expressed in mammalian tissues and is relatively more abundant in post-mitotic 
cells, suggesting that they possibly function in higher eukaryotes and exert the different biological 
function from cell cycle [4]. PCTK1, the best-characterized member of this kinase family, regulates 
neurite outgrowth in the Neuro2A neuroblastoma cell line [5], and is involved in the membrane 
trafficking through the early secretory pathway via phosphorylation of N-ethylmaleimide-sensitive 
fusion protein [6, 7]. Recent studies have been reported that PCT-1, the C. elegans ortholog of PCTK1, 
is complexed with CYY-1 (orthologous to mammalian cyclin Y, a novel membrane-associated cyclin) 
and also is necessary for targeting presynaptic components to the axon [8]. Furthermore, human 
PCTK1 has been shown to be activated by cyclin Y and be essential for spermatogenesis [9]. PCTK2 
is associated with Trap (tudor repeat associator with PCTAIRE 2) and ik3-1/cables, the adaptor that 
functionally connects c-abl and CDK5 to support neurite growth [10, 11]. The third member of this 
family PCTK3 is the least well-studied. Although exogenously expressed PCTK1 and PCTK2 
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phosphorylate myelin basic protein and histone H1 in vitro, PCTK3 kinase activity has been not 
detected. To elucidate regulatory mechanism of PCTK3 activity, it is necessary for identifying 
activators of PCTK3. 
 
2.2. Cyclin A 
Cyclin A consists of two isoforms, cyclin A1 and cyclin A2, in mammal. Cyclin A1 is expressed 
predominantly in germ cells, and is required for the entry of germ cells into the first meiotic division 
in male mouse [12]. In contract, cyclin A2 is ubiquitously expressed in somatic cells, and it has a 
major role in progression of S phase and transition of G2/M phase through activation of CDK2 and 
CDK1, respectively. Although cyclin A predominantly localizes in the nucleus during S phase, it also 
shuttles between the nucleus and cytoplasm and is degraded by ubiquitin-mediated proteolysis during 
G2 phase. It was reported that cyclin A/CDK2 was transiently maintained by SCAPER, S phase cyclin 
A-associated protein, in the cytoplasm [13]. On the other hand, a recent study showed cyclin A2 was 
involved in the regulation of cell migration and invasiveness through direct interaction with RhoA, 
suggesting a novel function of cyclin A in a CDK1- and CDK2-independent manner. [14] 
 
2.3. cAMP/PKA Signaling Pathway 
cAMP, an intracellular second messenger, is involved in the regulation of various cell functions 
including blood glucose level, immune function, and neural function. cAMP is synthesized by 
hormone-mediated adenylate cyclase activation. Increased intracellular cAMP levels lead to activation 
of its target proteins, such as cAMP-dependent kinase (PKA) [15, 16], while synthesized cAMP is 
eventually degraded to adenosine monophosphate by phosphodiesterase [17]. PKA is constituted by 
two catalytic subunits (C) and two regulatory subunits (R). cAMP stimulates the dissociation of 
regulatory subunits and catalytic subunits, resulting in the PKA activation (Fig. 3). Activated PKA 
exerts phosphorylation activity toward the following consensus sequence Arg–Arg–X–Ser/Thr (X 
represents any amino acid) [18]. PKA also plays an important role in maintaining meiotic arrest [19]. 
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In Xenopus oocyte, PKA phosphorylates and inactivates Cdc25C phosphatase, whereas Wee1B kinase 
activity is enhanced by PKA [20, 21]. The activity of cyclin B/CDK1 complex is controlled by Wee1 
kinases and Cdc25C phosphatases [22, 23]. PKA regulates the activity of cyclin B/CDK1 complex via 
dual regulation of the Cdc25 phosphatase and Wee1B kinase [20]. On the other hand, PKA 
phosphorylates PCTK1 at Ser119 and Ser153, and phosphorylation of PCTK1 on Ser153 inhibits the 
interaction between PCTK1 and cyclin Y, that is to say, PKA inactivates PCTK1 activity [5, 9]. Thus, 
PKA regulates the activity of CDK in a direct or indirect manner. 
 
Figure 1. PKA signaling pathway 
 
2.4. Rho GTPases Regulate Actin Cytoskeleton 
Cell migration is a typical cell function common to eukaryotic cells, which is associated with 
variously physiological phenomena, such as organogenesis, neural network formation, cancer invasion 
and metastasis [24, 25]. Cell migration is generally achieved by three processes: (1) protrusion of 
pseudopodia, including lamellipodia and filopodia, at cell front (2) adhesion of pseudopodia to 
surrounding tissues or extracellular matrix (ECM), and (3) traction of the cell body toward the front 
[26(3)]. These processes are controlled by cytoskeleton including actin fiber, microtubule, and 
intermediate filament [27]. The distribution of cytoskeleton is substantially altered in response to the 
extracellular stimulation or cell cycle progression, giving mechanical strength and contractile force to 
cell body [28]. Actin cytoskeleton is constituted by the actin filament and actin binding proteins and 
controlled by cross-talk between actin binding proteins and the Rho GTPase family, such as RhoA, 
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Rac1, and Cdc42 [29]. The Rho GTPase family regulates the fundamental processes including cell 
movement, polarity, and division in eukaryotic cells [30]. Conversion between active GTP-bound state 
and inactive GDP-bound state of Rho GTPase is controlled by guanine nucleotide exchanging factor 
(GEF) [31], GTPase-activating protein (GAP) [32], and guanine nucleotide dissociation inhibitors 
(GDI) [33] (Fig. 1). Active GTP-bound Rho GTPase leads to the assembly of stress fiber and 
characteristic membrane protrusion, such as lamellipodia and filopodia, through coordinating their 
effector proteins [29]. A number of effector proteins of Rho GTPases have been identified so far, 
including serine/threonine kinases, tyrosine kinases, lipid kinases, lipases, oxidases, and scaffold 
proteins [34]. Rho-associated kinase (ROCK) is one of the effector proteins of RhoA, which promotes 
the actin crosslinking activity of myosin II via phosphorylating myosin light chain (MLC) [35]. ROCK 
is also involved in the regulation of actin polymerization through modulating the LIM-domain kinase 
(LIMK)/cofilin signal transduction [36]. Thus, RhoA/ROCK signaling pathway plays important roles 
in the regulation of actin cytoskeleton and cell motility. 
 
Figure 2. Basic model of Rho GTPase regulation 
 
2.5. Focal Adhesion 
In multicellular organism, cells are attached to surrounding ECM via adhesion receptors [37]. 
ECM is constituted by filament proteins, proteoglycan, or polysaccharide, which is essential for the 
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regulation of cell survival, differentiation, proliferation, and motility [38]. Cells are attached to ECM 
through focal adhesion which mediates the mechanical force to intracellular signal [39]. Focal 
adhesion is also connected with the actin cytoskeletal network including actin binding proteins and 
Rho GTPases [40]. Actin cytoskeletal networks give the physical strength to cells, maintain the cell 
shape, and translate the mechanical force to intracellular organelles [41]. The balance of focal 
adhesion assembly and disassembly is important for cell spreading and migration. During the early 
stages of cell adhesion, minute dot-like structures, called focal complex, are appeared at lamellipodia 
or filopodia. Focal complex is disassembled in short term (within several minutes), or grows to focal 
adhesion. Focal adhesion is eventually matured to stable assembly, called fibrillar adhesion (Fig. 2). 
These adhesion assembles (focal complex, focal adhesion, and fibrillar adhesion) are constituted by 
different molecules, respectively [42]. Focal adhesion is constituted by various proteins, such as 
ECM-interacting proteins (for instance, integrin, which is the heterodimer consisted of α-chain and 
β-chain), integrin-actin crosslinking proteins (talin, α-actinin, and tensin), tyrosine kinases (focal 
adhesion protein kinase (FAK) and Src), and substrates of tyrosine kinases (paxilin and p130Cas) [39]. 
These proteins transduce their signal to downstream molecules in response to the binding of ECM to 
integrin, resulting in the regulation of cell proliferation, differentiation, and motility [43].  
 
Figure 3. Formation and development of focal adhesion  
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Chapter 3. Introduction 
 PCTAIRE kinase 3 (PCTK3)/cyclin dependent kinase 18 (CDK18) is a member of the CDK family 
[44]. Although the PCTK3 is relatively more abundant in post-mitotic cells, their enzymatic 
characteristic and physiological function have remained unknown because of unidentified its 
activator(s) [4]. In this study, I demonstrated that PCTK3 is activated by association with cyclin A2 
and phosphorylates retinoblastoma protein (Rb) in vitro. Additionally, I noted that PCTK3 contains 
some putative PKA phosphorylation sites (Arg-Arg-X-Ser/Thr), and that the phosphorylation of 
PCTK3 by PKA resulted in an increase in its catalytic activity, even in the absence of the cyclin A2. 
Furthermore, I also found that PCTK3 is involved in the regulation of actin cytoskeleton via 
negatively regulating FAK and RhoA activities. These findings may provide insight into the function 
of PCTK3. 
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Chapter 4. Experimental Procedures 
4.1. Antibodies and Materials  
Antibody against cyclin A was purchased from BD Biosciences, and anti-cyclin B1, anti-cyclin 
D1, anti- cyclin E1, anti-cyclin E2, anti-cyclin H, anti-CDK1, anti-CDK2, anti-phospho-Rb (Ser795) 
and (Ser807/811), anti-phospho-cofilin (Ser3) and anti-phospho-PKA substrate (RRXS/T), 
anti-phospho-FAK (Tyr397), anti-FAK, anti-phospho-Src family (Tyr416), anti-phospho-Src (Try527) and 
anti-Src antibodies were from Cell Signaling Technology. Anti-PCTK3, anti-α-tubulin and anti-β-actin 
antibodies were from Santa Cruz Biotechnology. Anti-FLAG M2 antibody was form Sigma-Aldrich. 
Anti-GST antibody was from Wako Pure Chemical Industries. Anti-Strep antibody was from Qiagen. 
Alexa-555 conjugated-phalloidin was from Cytoskeleton. 
 
4.2. Plasmid Construction 
cDNAs encoding mouse full-length PCTK1, PCTK2, PCTK3, CDK2, PFTK1, cyclin A2, cyclin 
E1, cyclin K, and cyclin Y and human retinoblastoma protein (779-928 amino acid; Rb C) were cloned 
by PCR using the respective specific primers. PCR products were cloned into TA-cloning vector 
pGEM-T Easy (Promega), and the inserted DNA sequences were confirmed by DNA sequencing. The 
inserted DNAs were subcloned in frame into the different mammalian expression vectors including 
Strep-tagged expression vector pEXPR-IBA105 (IBA GmbH), glutathione S-transferase (GST) fusion 
expression vector pEBG and FLAG-tagged expression vector pFLAG-CMV-2 (Sigma-Aldrich). A 
cDNA encoding for human Rb C was subcloned into the pMAL vector (New England Biolabs) of the 
bacterial maltose binding protein (MBP) fusion expression system. The expression plasmid 
pFLAG-PKA-C encoding the catalytic subunit α isoform of mouse PKA was described previously [45]. 
Site-directed mutagenesis was performed using PrimeSTAR Mutagenesis Basal Kit (Takara Bio) 
according to the manufacturer’s instructions. The mutation was confirmed by DNA sequencing 
analysis.  
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4.3. Expression and Purification of Rb Recombinant Protein 
The bacterial expression plasmid of Rb, pMAL-Rb C, was introduced into the bacterial strain 
BL21 Star DE3 (Life Technologies). An overnight culture in LB medium was diluted fresh LB 
medium and incubated at 37 °C in a shaking incubator for 1 hour. After 
isopropyl-1-thio-β-D-galactopyranoside was added to the culture to a final concentration of 0.2 mM, 
the culture was incubated at 30 °C for an additional 6 hours. The cells were resuspended in ice-cold 
soluble buffer (20 mM Tris-HCl, pH 8.0, 1 mM EDTA, 10 mg/ml aprotinin and 10 mM leupeptin). 
After freezing and thawing, suspended cells were sonicated on ice in short bursts. The lysate was 
cleared by centrifugation at 10,000 x g for 10 minutes at 4 °C. The supernatant was then incubated 
with amylose resin (New England Biolabs) for overnight at 4 °C. The beads were washed five times 
with ice-cold soluble buffer and incubated with 10 mM maltose at 4 °C to elute fusion protein from the 
beads. After centrifugation, the supernatant was dialyzed against phosphate-buffered saline (PBS). The 
purified proteins were electrophoresed on SDS-PAGE and visualized by Coomassie brilliant blue 
staining, and the protein concentration was determined by Bradford assay (Bio-Rad) using bovine 
serum albumin as a standard. 
 
4.4. Cell Culture and Transfection 
COS-7, HeLa and HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin at 
37 °C in 5% CO2. Cells were transfected with various expression vectors using Lipofectamine 2000 
(Life Technologies), according to the manufacturer’s instructions. 
 
4.5. Subcellular Fractionations 
HEK293T cells were washed twice with ice-cold PBS, harvested by scraping, and lysed in a 
buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 10 μg/ml leupeptin and 10 μg/ml 
aprotinin). After incubation on ice for 15 minutes, the cells were added with 0.5% NP-40 and 
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homogenized by vortex for 10 seconds. The homogenate was centrifuged at 2500 rpm for 3 minutes to 
sediment the nuclei. The supernatant was then centrifuged at a 10,000 rpm for 10 minutes, and the 
resulting supernatant formed the cytoplasm fraction. The nuclear pellet was washed three times with 
buffer A to remove any contamination from cytoplasmic proteins. To extract nuclear proteins, the 
isolated nuclei were resuspended in buffer B (20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA, 10 
μg/ml leupeptin and 10 μg/ml aprotinin), and the mixture was incubated on ice for 20 minutes. 
Nuclear lysates were collected after centrifugation at 12,000 rpm for 15 minutes at 4 °C. The purity of 
nuclear and cytoplasm fractions was confirmed using anti-lamin B1 antibody (MBL) as a nuclear 
marker and α-tubulin antibody as a cytoplasmic marker, respectively. 
 
4.6. Pull-down and Co-immunoprecipitation Assays 
Pull-down and co-immunoprecipitation assays were performed as previously described [46]. 
Briefly, cells were scraped in an ice-cold TNE buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% 
NP-40 and 1 mM EDTA) supplemented with protease inhibitors (10 μg/ml leupeptin and 10 μg/ml 
aprotinin). The cell extracts were centrifuged at 10,000 x g for 10 minutes at 4 °C prior to 
immunoprecipitation or immunoblotting. Equal protein amounts of the lysates were analyzed for 
protein expression. For pull down assay, lysates were incubated with Strep-Tactin Sepharose (IBA 
GmbH) or glutathione Sepharose (GE Healthcare) for overnight at 4 °C. For immunoprecipitation, 
lysates were incubated with anti-FLAG M2 or anti-PCTK3 antibody in the presence of protein G 
Sepharose (GE Healthcare) for overnight h at 4 °C. The beads were washed forth with wash buffer (20 
mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% NP-40 and 1 mM EDTA). Precipitated proteins were 
subjected to in vitro kinase assay or immunoblot analysis. Protein expression and phosphorylation 
were determined by immunoblot of immunoprecipitates or total cell lysate. The RhoA and Rac1 
activities were measured by RhoA Pull-down Activation Assay Biochem Kit or Rac1 Pull-down 
Activation Assay Biochem Kit (Cytoskeleton) according to the manufacture’s instruction. Cells were 
washed with PBS and lysed in ice-cold Cell Lysis Buffer (50 mM Tris-HCl, pH7.5, 10 mM MgCl2, 40 
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mM NaCl, 62 μg/ml Leupeptin, 62 μg/ml Pepstatin A, 14 mg/ml Benzamidine and 12 mg/ml tosyl 
arginine methyl ester). Cell lysates were centrifuged at 10,000 g, 4 °C for 1min. Equal protein amounts 
of the lysates (300 – 800 μg) were incubated with Rhotekin/ or PAK-RBD Protein beads at 4 °C on a 
rotator for 2 hours. After incubation, the beads were washed with wash buffer (25 mM Tris-HCl, pH 
7.5, 10 mM MgCl2, 0.5 M NaCl and 2 % Igepal). The amount of bound RhoA or Rac1 were analyzed 
by immunoblot and normalized to the total RhoA of Rac1. Quantitation was performed using Image J. 
 
4.7. Transfection of Small Interference RNA 
The synthetic small interfering RNA (siRNA) oligonucleotides were purchased from 
Sigma-Aldrich. siRNAs were targeting human PCTK3 on nucleotides 530-549 in NM_ 002596 for 
PCTK3 siRNA#1 (ID# SASI_Hs02_00334101), on nucleotides 1286-1305 for PCTK3 siRNA#2 (ID# 
SASI_Hs01_00015475) and on nucleotides 692-710 for PCTK3 siRNA#3 (ID# 
SASI_Hs01_00015476). A MISSION siRNA Universal Negative Control #1 was used as negative 
control. The transfection of siRNA was performed using Lipofectamine 2000 according to the 
manufacturer’s instructions. 
 
4.8. In Vitro Kinase Assay 
In vitro kinase assay was carried out as previously described [46]. For in vitro kinase assay of 
PCTK3, cell lysates were incubated with a glutathione Sepharose or immunoprecipitated with 
anti-PCTK3 antibody and protein G Sepharose overnight at 4 °C by rotation. The beads were washed 
three times with wash buffer and twice with 50 mM Tris-HCl, pH7.5. The kinase reaction was carried 
out by resuspending the complexes in 100 µl of kinase buffer [50 mM Tris-HCl pH 7.5, 20 mM 
magnesium acetate, 20 μM or 50µM ATP and phosphatase inhibitor cocktail (Nacalai Tesque)] 
including 5 μg/ml purified MBP-Rb C in the absence or presence of 2 μCi [γ-32P] ATP and incubating 
for 30 minutes at 30 °C. Phosphorylated MBP-Rb C was separated by SDS-PAGE and visualized with 
a BAS-1500 Bioimaging Analyzer (Fuji Film) or subjected to immunoblot analysis using 
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anti-phospho-Rb (Ser795). To assay the phosphorylation of PCTK3 by PKA, cell lysate were 
immunoprecipitated with anti-FLAG for overnight at 4 °C by rotation. The kinase reaction was carried 
out by resuspending the complexes in 100 µl of kinase buffer with 2 μCi [γ-32P] ATP and incubating 
for 30 minutes at 30 °C. Immunocomplexes were eluted by heating at 95 °C in 6 x SDS loading buffer, 
subjected to SDS-PAGE, and visualized by BAS-1500 Bioimaging Analyzer. Quantitative 
densitometric analysis was performed using Image J software. 
 
4.9. In Vivo Kinase Assay 
HEK293T cells were treated with 10 µM forskolin for 30 minutes and scraped in an ice-cold TNE 
buffer supplemented with phosphatase inhibitor cocktail. The cell extracts were centrifuged at 10,000 
x g for 10 minutes at 4 °C to remove cellular debris, and the supernatants were immunoprecipitated 
with anti-PCTK3 antibody with protein G-Sepharose for overnight at 4 °C by rotation. The beads were 
washed with wash buffer, and immunocomplexes were eluted by heating at 95 °C in 6 x SDS loading 
buffer, subjected to SDS-PAGE, and immunoblotted using anti-phospho-RRXS/T antibody. 
 
4.10. Immunofluorescence Analysis 
Immunofluorescence analysis was performed as previously described [46]. In brief, HEK293T 
cells grown on poly-L-lysine-coated chamber slides were cotransfected with FLAG-PCTK3 and 
Myc-cyclin A2. At 24 hours post-transfection, cells were washed twice with PBS and fixed for 20 
minutes in 3.7% formaldehyde. Following sequential washes with PBS, cells were permeabilized for 5 
minutes in 0.1% Triton X-100, washed three times with PBS, and then treated with 5% bovine serum 
albumin for 30 minutes. Cells were subsequently incubated with mouse anti-FLAG M2 IgG or rabbit 
anti-Myc polyclonal antibody for overnight at 4 °C. Following three washes with PBS, cells were 
incubated for 1 hour with goat anti–mouse IgG directly conjugated to Alexa Fluor 488 or goat anti–
rabbit IgG directly conjugated to Alexa Fluor 555 (Life Technologies). The slides were washed 
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thoroughly with PBS and mounted in fluorescent mounting medium Vectashield (Vector Laboratories). 
A confocal laser-scanning microscope (Leica TCS-SP5) was used to obtain staining profiles.  
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Chapter 5. Results 
5.1. Identification of Cyclin A2 as an Activator of PCTK3 
A recent report revealed that PCTK1, a member of the PCTK subfamily, was activated by 
membrane-associated cyclin Y [9, 47]. I hypothesized that PCTK3 is also activated by cyclin family 
members. To identify activators of PCTK3, I expressed a Strep-tagged mouse PCTK3 in human 
embryonic kidney HEK293T cells and conducted Strep pull-down experiments. Proteins 
coprecipitated with PCTK3 were analyzed by an immunoblot assay using anti-cyclin A, B1, D1, E1, 
E2, and H antibodies. Immunoblot analysis revealed that PCTK3 interacts with cyclin A and cyclin E1, 
but not cyclin B1, D1, E2 and H, in HEK293T cells (Fig. 4A). To confirm the interaction between 
PCTK3 and cyclin A2 or E1, GST pull-down experiment with lysates from COS-7 cells expressing 
GST-fused PCTK3 and FLAG-tagged cyclins was performed. Additionally, I also examined whether 
cyclin K and cyclin Y binds to PCTK3, because PCTK3 was found to interact with cyclin K in a 
large-scale interaction study [48]. As shown in Fig. 4B, GST-PCTK3 is associated with FLAG-cyclin 
A2 and cyclin E1, but not with cyclin K and cyclin Y. 
Subsequently, to examine whether PCTK3 activity is regulated by binding of cyclin A2 or cyclin 
E1, I carried out in vitro kinase assay using retinoblastoma protein (Rb) as a substrate. Rb is 
phosphorylated by some CDKs in a cell cycle-dependent manner, and PFTAIRE kinase 1 (PFTK1), 
which is activated by cyclin D3 and cyclin Y, also phosphorylates Rb [49, 50]. The C-terminus of Rb 
contains a cluster of seven candidate CDK phosphorylation sites (Ser/Thr-Pro motifs; Ser780, Ser788, 
Ser795, Ser807, Ser811, Thr821, and Thr826) [51]. For in vitro kinase assay, I produced recombinant 
maltose-binding protein (MBP)-fused Rb C (amino acids 779–928) in E. coli. COS-7 cells were 
cotransfected with GST-PCTK3 in the presence or absence of FLAG-cyclin A2 or E1, and cell lysates 
were subjected to glutathione-Sepharose pull-down. An in vitro kinase analysis with [γ-32P] ATP 
demonstrated that MBP-Rb C was phosphorylated by PCTK3 in the presence of cyclin A2, whereas 
cyclin E1 did not activate PCTK3 (Fig. 4C). Furthermore, an in vitro kinase assay using myelin basic 
protein (MyBP) and histone H1 as substrates was performed. As shown in Fig. 4D, cyclin A2/CDK2   
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Figure 4. Identification of cyclin A2 as an activator of PCTK3. A, HEK293T cells were transfected 
with Strep-PCTK3. After the Strep pull down assay, the precipitated proteins were subjected to 
immunoblot analysis with anti-cyclin A, anti-cyclin B1, anti-cyclin D3, anti-cyclin E1, anti-cyclin E2, 
and anti-cyclin H antibodies. Total cell lysates were used as the input samples and positive control. B, 
GST-PCTK3 was expressed in COS-7 cells with either FLAG-cyclin A2, FLAG-cyclin E1, 
FLAG-cyclin K or FLAG-cyclin Y. In the control experiment (GST-PCTK3 (-)), GST alone was 
expressed instead of GST-PCTK3. The GST pull-down precipitates were immunoblotted with 
anti-FLAG antibody. Protein expression was confirmed by immunoblotting total cell lysates. C, GST 
and GST-PCTK3 was expressed with either FLAG-cyclin A2 or FLAG-cyclin E1 in COS-7 cells. 
After the GST pull down, the precipitated samples were incubated in a kinase buffer containing [γ-32P] 
ATP and MBP-Rb C for 30 minutes. The supernatants containing MBP-Rb C were separated on 
SDS-PAGE, after which the gel was analyzed by bioimaging analyzer. The expression level of 
GST-fused and FLAG-tagged proteins was confirmed by immunoblotting with anti-FLAG and 
anti-GST antibody, respectively. D, COS-7 cells were transfected with Strep-PCTK3 and 
FLAG-cyclin A2. GST pull downed proteins were incubated in a kinase buffer containing MBP-Rb C 
for 30 minutes. The precipitates and supernatants were analyzed by SDS-PAGE and immunoblotting 
with anti-FLAG and anti-phospho-Rb (Ser795) and (Ser807/811) antibodies, respectively. D, COS-7 cells 
were transfected with Strep-PCTK3, Strep-CDK2 and FLAG-cyclin A2. Strep pull-downed proteins 
were incubated in a kinase buffer containing MyBP, MBP-Rb C or Histone H1 for 30 minutes. The 
supernatants were analyzed by SDS-PAGE and bioimaging analyzer. E, Strep-PCTK3 was expressed 
in COS7 cells with FLAG-cyclin A2. After the Strep pull-down, bound proteins were incubated in a 
kinase buffer containing MBP-Rb C for 30 minutes. The precipitates and supernatants were analyzed 
by SDS-PAGE and immunoblotting with anti-FLAG and anti-phospho-Rb (Ser795) and (Ser807/811) 
antibodies, respectively.  
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complex strongly phosphorylated all three substrates tested (Rb, MyBP and histone H1). On the other 
hand, catalytic activity of PCTK3 was much less than that of CDK2 even in the presence of cyclin A2. 
Among three substrates tested, Rb was most efficiently phosphorylated by cyclin A2/PCTK3 complex. 
Additionally, phosphorylated MBP-Rb C was detected using antibodies against phospho-Rb (Ser795) 
and phospho-Rb (Ser807/811) (Fig. 4E). Both antibodies detected Rb phosphorylation only when PCTK3 
was complexed with cyclin A2, indicating that cyclin A2/PCTK3 complex phosphorylates Rb at least 
at Ser795 and Ser807/811 in vitro. These results revealed that PCTK3 is activated through association with 
cyclin A2. 
 
5.2. Cyclin A2 Specifically Activates PCTK3 
Cyclin A2 has been shown to interact with CDK1 and CDK2 during cell cycle [52]. To evaluate 
whether the phosphorylation of Rb is dependent on PCTK3 or other kinases coprecipitated with cyclin 
A2, I performed GST-pull down experiments. As shown in Fig. 5A, endogenous CDK1 and CDK2 
were specifically coprecipitated with GST-cyclin A (lane 4), while GST-PCTK3, 
GST-PCTK3/FLAG-cyclin A2 complex, and FLAG-cyclin A2 did not coprecipitate endogenous 
CDK1 and CDK2 (lane1-3). Furthermore, I designed PCTK3 inactive mutant based on amino acids 
conserved between various members of the CDK family. The analogous K194R mutation at the 
putative ATP binding site of PCTK1 has been reported to generate kinase dead mutants [5]. A 
kinase-dead mutant of PCTK3 in which the putative ATP binding site was replaced by arginine 
(PCTK3 K150R) was created and tested by in vitro kinase assay. Although both PCTK3 wild-type and 
K150R were interacted with cyclin A2, PCTK3 K150R activity was almost completely lost (Fig. 5B). 
These results indicated that the phosphorylation of Rb is dependent on PCTK3 but not other kinases, 
and strongly supported that cyclin A2 is an activator of PCTK3.  
Furthermore, I examined whether other members of the PCTK subfamily, PCTK1 and PCTK2, is 
activated by cyclin A2, because activators of PCTK2 have not yet been identified. Interestingly, 
although PCTK1 and PCTK2 were interacted with cyclin A2, only PCTK3 was activated by cyclin A2 
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(Fig. 5C). On the other hand, PFTK1 with high homology to PCTK3 was not even associated with 
cyclin A2, and was also unable to phosphorylate Rb C (Fig. 5D). However, GST-pull down and in 
vitro kinase assays showed that CDK2 had a greater affinity for cyclin A2 than PCTK3, and that 
catalytic activity of PCTK3 was much less than that of CDK2 in the presence of cyclin A2 (Fig. 5D). 
These results demonstrated that cyclin A2 specifically activates PCTK3, and implied the existence of 
other activators of PCTK3 besides cyclin A2. 
 
 
Figure 5. Cyclin A2 specifically activates PCTK3. A, COS-7 cells were transfected with 
GST-PCTK3, FLAG-cyclin A2 and GST-cyclin A2. In the control experiment, GST alone was 
transfected instead of GST-PCTK3 or GST-cyclin A2. The GST pull-down precipitates were subjected 
to immunoblotting with anti-FLAG, anti-CDK1, and anti-CDK2 antibodies. B, GST-PCTK3 wild type 
(WT) or K150R mutant was expressed in COS-7 cells with FLAG-cyclin A2. In the control 
experiment, GST alone was expressed instead of GST-PCTK3. After the GST pull down, the bound 
proteins were incubated in a kinase buffer with MBP-Rb C. The precipitates and supernatants were 
analyzed by SDS-PAGE and immunoblotting with anti-FLAG and anti-phospho-Rb (Ser795) antibodies, 
respectively. C, FLAG-cyclin A2 was expressed in COS-7 cells with GST, GST-PCTK1, GST-PCTK2 
or GST-PCTK3. The GST pull-down precipitates were subjected to in vitro kinase assay using 
anti-phospho-Rb (Ser795) antibody. D, GST, GST-PCTK3, GST-PFTK1, or GST-CDK2 was expressed 
in COS-7 cells with FLAG-cyclin A2. The GST pull downed proteins were subjected to in vitro kinase 
assay. 
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5.3. Endogenous Interaction between PCTK3 and Cyclin A2 in Cytoplasm 
Next, I examined the endogenous interaction between PCTK3 and cyclin A2. A previous study 
reported that PCTK3 protein is expressed in some cell lines including HEK293 cells [6]. Thus, I 
confirmed whether PCTK3 expression was detectable in some cell lines. As shown in Fig. 6A, 
anti-PCTK3 antibody detected a specific protein band with the predicted molecular mass of PCTK3 in 
HEK293T cells, while its expression was very low or absent in human breast carcinoma MCF7cells 
and human cervical carcinoma HeLa cells. PCTK3 expression in HEK293T cells was confirmed by 
knock down analysis using siRNA. As shown in Fig. 6B, PCTK3 expression was efficiently reduced 
by each of three PCTK3 siRNA, whereas negative control siRNA had no effect on PCTK3 expression.  
 
 
 
Figure 6. Endogenous interaction between PCTK3 and cyclin A in the cytoplasm. A, Immunoblot 
analysis of total proteins prepared from HeLa, MCF7 and HEK293T human cell lines. β-actin was 
used as a loading control. B, siRNA knockdown of PCTK3 in HEK293T cells. Cells were transfected 
with three different siRNAs against PCTK3. Forty-eight hours after transfection, cell extracts were 
immunoblotted with anti-PCTK3 antibody. Expression of β-actin was used as a loading control. C, 
Subcellular localization of endogenous PCTK3 and cyclin A. HEK293T cells were separated into 
nuclear and cytoplasmic fractions as described in EXPERIMENTAL PROCEDURES. Aliquots of 
each fraction were immunoblotted for PCTK3 and cyclin A. The purity of nuclear and cytoplasmic 
fractions was confirmed using anti-lamin B1 antibody as a nuclear marker and α-tubulin antibody as a 
cytoplasmic marker, respectively. D, Endogenous interaction between PCTK3 and cyclin A in 
HEK293T cells. The fractionated lysates from HEK293T cells were immunoprecipitated using 
anti-PCTK3 antibody. The immunoprecipitates were analyzed by immunoblotting with anti-cyclin A 
antibody. Normal rabbit IgG (IgG) was used as a control. 
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Furthermore, I examined the distribution of PCTK3 and cyclin A between nucleus and cytoplasm 
using a simple cell fractionation. PCTK3 protein appeared in the cytoplasm, while cyclin A was 
localized to both the cytoplasm and nucleus (Fig. 6C). I then immunoprecipitated PCTK3 from 
cytoplasmic and nuclear fractions of HEK293T cells using anti-PCTK3 antibody, and 
immunoprecipitates were assayed by immunoblotting with anti-cyclin A antibody. Cyclin A was 
detected in the cytoplasmic PCTK3 immunoprecipitates but not in the nuclear (Fig. 6D), indicating 
that PCTK3 indeed interacts with cyclin A in vivo. 
 
 
 
Figure 7. Subcellular localization of PCTK3 and cyclin A2. A and B, HEK293T cells were 
cotransfected with Myc-cyclin A2 together with either FLAG-PCTK3 (A) or FLAG-CDK2 (B). Cells 
were fixed and incubated with mouse anti-FLAG and rabbit anti-Myc antibodies. The primary 
antibody was visualized with Alexa Fluor 488-conjugated anti-mouse IgG and Alexa Fluor 
555-conjugated anti-rabbit IgG, followed by confocal microscopy. Fluorescence for FLAG-PCTK3 or 
FLAG-CDK2 (green) and Myc-cyclin A2 (red) is shown with the merged images (merge is in yellow). 
Hoechst nuclear staining is represented in blue. C, Fluorescence intensities in the nuclear (N, closed 
bar) and cytoplasmic (C, open bar) regions were quantified using Image J software. The data shown 
are the means ± S.E. (n ≥ 5). 
 
To visualize the subcellular distribution of PCTK3 and cyclin A2, FLAG-PCTK3 and Myc-cyclin 
A2 were cotransfected into HEK293T cells and examined by immunofluorescence analysis using 
confocal laser-scanning microscope. FLAG-PCTK3 was present at the cytoplasm and Myc-cyclin A2 
was distributed in the cytoplasm and nucleus (Fig. 7A), consistent with a simple cell fractionation 
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experiment (Fig. 6C). The merged data showed significant overlap between FLAG-PCTK3 and 
Myc-cyclin A (Fig. 7B), indicating that cyclin A is colocalized with PCTK3 in the cytoplasm. On the 
other hand, cyclin A was colocalized with CDK2 in the nucleus (Fig. 7B). Interestingly, cyclin A 
expression in the cytoplasm was enhanced by coexpression of PCTK3 compared with that of CDK2 
(Fig.7C), suggesting that PCTK3 regulates the localization and stability of cyclin A2 in the cytoplasm. 
Together, these findings demonstrate that PCTK3 is interacted with cyclin A in the cytoplasm. 
 
5.4. PCTK3 Protects Cyclin A2 against Degradation in Cytoplasm 
It is known that cyclin A2 is degraded in prometaphase by anaphase-promoting 
complex/cyclosome and its process is necessary for mitosis progression [53(59)]. I hypothesized that 
cyclin A2 is protected from degradation by PCTK3 in cytoplasm. Thus, to analyze whether PCTK3 
regulates the stability of cyclin A2, I investigated the expression level of cyclin A2 in PCTK3 
 
Figure 8. PCTK3 protects cyclin A2 
against degradation in the cytoplasm. 
A. HEK293T cells were transfected with 
PCTK3 siRNA. The cell lysates were 
subjected to immunoblotting with 
anti-PCTK3 and anti-cyclin A 
antibodies. Expression of α-tubulin was 
used as a loading control. B, HEK293T 
cells were cotransfected with GST or 
GST-PCTK3, together with 
FLAG-cyclin A2. After 24 hours, 
cycloheximide (CHX) (5 µg/ml) was 
added to the cell culture. Cells were 
harvested at indicated times after 
cycloheximide treatment and 
FLAG-cyclin A2 expression levels were 
determined by immunoblotting (IB: 
anti-FLAG). β-actin was used as a 
loading control (IB: anti-β-actin). 
FLAG-cyclin A2 expression levels were 
quantified by densitometric analysis and 
represented in a graph. 
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knockdown HEK293T cells. As expected, PCTK3 knockdown cells show a reduction in the expression 
level of cyclin A2 relative to negative control siRNA-treated cells (Fig. 8A). Furthermore, to verify the 
protective effect of PCTK3 against degradation of cyclin A2, HEK293T cells cotransfected with 
FLAG-cyclin A2 and GST-PCTK3 were treated with cycloheximide, a protein synthesis inhibitor. The 
cells were harvested at indicated times after treatment, and total cell lysates were subjected to 
immunoblot analysis. As shown in Fig. 8B, the expression level of cyclin A2 in the absence of 
GST-PCTK3 was clearly decreased, whereas cyclin A2 expression in the presence of GST-PCTK3 
was slightly decreased. These results suggest that PCTK3 may protect the cyclin A2 from degradation.  
 
5.5. PCTK3 is Phosphorylated by PKA in Vitro and in Vivo 
PKA is an essential factor which is concerned with many of the various physiological functions, 
including cytoskeletal organization, cell motility, and signal transduction [54]. PKA has been reported 
to preferentially phosphorylate serine/threonine residues within the consensus sequence 
Arg-Arg-X-Ser/Thr [18]. A previous report demonstrated that PKA inactivates PCTK1 via 
phosphorylation at Ser153 [5]. Amino acid sequence analysis revealed that mouse and human PCTK3 
contain four putative phosphorylation sites (RRLS12, RRFS66, RRAS109 and RRQS449 in mouse and 
RRFS14, RRFS89, RRAS162 and RRQS502 in human) for PKA, respectively, suggesting that PCTK3 is a 
substrate for PKA. To examine whether endogenous PCTK3 is phosphorylated by PKA, HEK293T 
cells were treated with an adenylate cyclase activator, forskolin. Cell lysates were immunoprecipitated 
with anti-PCTK3 antibody, and immunoblot analysis using an anti-phospho RRXS/T antibody was 
examined. As shown in Fig. 9A, PCTK3 protein was specifically precipitated by anti-PCTK3 antibody 
and was efficiently phosphorylated by treatment with forskolin. Next, I examined whether PKA 
directly phosphorylates PCTK3. COS-7 cells were cotransfected with FLAG-PCTK3 and FLAG-PKA 
catalytic subunit, and in vitro kinase assay was carried out. As shown in Fig. 9B, PKA directly 
phosphorylated PCTK3. Furthermore, to identify phosphorylation sites of PCTK3 by PKA, four 
nonphosphorylatable mutants of mouse PCTK3 in which each of the putative   
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Figure 9. PCTK3 is phosphorylated by PKA in vitro and in vivo. A, Endogenous PCTK3 is 
phosphorylated by PKA. HEK293T cells were treated with 10 µM forskolin for 30 minutes. Cell 
lysates were immunoprecipitated with anti-PCTK3 antibody. Immunoprecipitates were analyzed by 
immunoblot analysis using anti-phospho-RRXS/T or anti-PCTK3 antibodies. The bands of 
phosphorylated and total PCTK3 were indicated by arrows. B, FLAG-PKA C, FLAG-PCTK3 wild 
type (WT), and mutants (S12A, S66A, S109, S449, S12A/S66A/S109A/S449A (4SA), and 
S12A/S66A/S109A (3SA)) were expressed in COS-7 cells. Cell lysates were immunoprecipitated with 
anti-FLAG antibody. Immunoprecipitates were incubated with kinase buffer containing [γ-32P] ATP. 
Equal amounts of cell lysates were analyzed by immunoblotting with anti-FLAG antibody. The graph 
indicates the phosphorylation rate of PCTK3. The phosphorylation rate of wild-type PCTK3 was taken 
as 100%. C, The double or triple mutants of PCTK3 (S12A/S66A, S12A/S109A, S66A/S109A, and 
3SA) were subjected to in vitro kinase assay using PKA. D, HeLa cells were transfected with 
FLAG-PCTK3 wild type (WT) and mutants (S12A, S66A, S109A, and 3SA). After 24 hours, 
transfected cells were treated with 10 µM forskolin at 30 minutes. Cell extracts were subjected to 
immunoprecipitated with anti-FLAG antibody (IP: anti-FLAG). Immunoprecipitates were 
subsequently analyzed by immunoblotting with anti-phospho-RRXS/T or anti-FLAG antibody. 
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PKA phosphorylation sites was replaced by alanine (S12A, S66A, S109A and S449A) were 
constructed and tested by the in vitro and in vivo kinase assay. Phosphorylation of S12A, S66A and 
S109A mutants was reduced compared with that of wild-type PCTK3, whereas the phosphorylation 
intensity of S449A mutant was almost equal to that of wild-type PCTK3 (Fig. 9B). Although PKA 
phosphorylated S12A/S66A, S66A/S109A, and S12A/S109A mutants of PCTK3 (Fig. 9C), it failed to 
phosphorylate S12A/S66A/S109A mutant (Fig. 9B and C). These results identified three serine 
residues (Ser12, Ser 66 and Ser109) as potential phosphorylation sites of mouse PCTK3 by PKA. 
Furthermore, phosphorylation sites of PCTK3 by PKA were confirmed by an in vivo kinase assay 
using an anti-phospho RRXS/T antibody. HeLa cells transiently transfected with FLAG-tagged 
PCTK3 were treated with 10µM forskolin. Cell lysates were immunoprecipitated with an anti-FLAG 
antibody, and then immunoblotted with anti-phospho RRXS/T antibody. As expected, forskolin 
treatment resulted in a 1.7-fold increase of PCTK3 phosphorylation, while phosphorylation of the 
S12A, S66A and S109A mutants was reduced compared with that of wild-type PCTK3 (Fig. 9D). 
These findings provide evidence that PCTK3 is phosphorylated by PKA at three sites (RRLS12, 
RRFS66 and RRAS109 in mouse) in vitro and in vivo. 
 
5.6. PCTK3 Activity Is Regulated via Phosphorylation at Ser12 by PKA 
I then investigated the effects of PKA phosphorylation of PCTK3 on its kinase activity. PCTK3 
activity was determined by GST-pull down and in vitro kinase assays using Rb C as the substrate. 
Three phospho-mimic PCTK3 mutants (PCTK3 S12D, S66D, and S109D), in which the PKA 
phosphorylation sites were replaced by aspartic acid, were generated, and the kinase activities of these 
phospho-mimic mutants were examined. As shown in Fig. 10A, the PCTK3 S12D mutant had 
relatively high activity for Rb phosphorylation, even in the absence of cyclin A2. Furthermore, the 
catalytic activity of the cyclin A2/S12D mutant complex was significantly increased (> 2-fold) as 
compared with that of cyclin A2/wild-type PCTK3, although the ability of S12D mutant to bind to 
cyclin A was not changed. By comparison, the PCTK3 S66D and S109D mutants had no effect on 
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kinase activity. On the other hand, the activity of the phospho-null mutant S12A was obviously 
decreased as compared with that of wild-type PCTK3 (Fig. 10B), strongly supporting that the 
phosphorylation at Ser12 influences the catalytic activation. In addition, the kinase activity of the 
PCTK3 S12D mutant was compared with that of the cyclin A2/CDK2 complex. Although cyclin 
A2/wild-type PCTK3 activity was six times less than that of cyclin A2/CDK2, the cyclin A2/S12D 
mutant had strong activity and reached a level comparable with the kinase activity of cyclin A2/CDK2 
(Fig. 10C).  
I also determined whether endogenous PCTK3 was activated by PKA. First, to determine 
endogenous PCTK3 activity, I immunoprecipitated PCTK3 from HEK293T cells transfected with 
negative control siRNA or PCTK3 siRNA and determined in vitro kinase activity using Rb as the 
substrate. As shown in Fig. 10D, significantly high Rb phosphorylation activity was detected in 
immunoprecipitates from cells transfected with negative control siRNA as compared with those from 
cells transfected with PCTK3 siRNA, suggesting that this activity was dependent on endogenous 
PCTK3 activity. Therefore, I assessed the effects of forskolin treatment on the kinase activity of 
PCTK3. Rb phosphorylation was significantly increased after forskolin treatment. These data 
demonstrated that PCTK3 is activated via phosphorylation at Ser12 by PKA.  
Several members of the CDK family preferentially phosphorylate the canonical motif Ser/Thr–
Pro–X–Lys/Arg/His (where X represents any amino acid). Because PCTK3 phosphorylated Rb in vitro, 
I investigated whether Rb was phosphorylated by PCTK3 in vivo. HEK293T cells were transfected 
with FLAG-tagged PCTK3 wild type or S12D mutant, after which cell lysates were subjected to 
immunoblotting using anti-phospho-Rb (Ser795). Both PCTK3 wild type and S12D failed to 
phosphorylate endogenous Rb, although Rb phosphorylation was detected in cyclin A2/CDK2 
transfected cells (Fig. 10E). This suggested that Rb is a poor substrate for PCTK3 in vivo, possibly due 
to its different subcellular localization.  
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Figure 10. PCTK3 activity is regulated via phosphorylation at Ser
12
 by PKA. A, COS-7 cell 
lysates expressing GST-PCTK3 mutants (S12D, S66D, S109D, and S12D/S66D/S109D) and 
FLAG-cyclin A2 were used in a kinase assay using Rb as the substrate. The relative kinase activity of 
PCTK3 was quantified by densitometric analysis. The activity of wild-type PCTK3 complexed with 
FLAG-cyclin A2 was taken as 1. Results are expressed as means ± S.E. from three independent 
experiments. Statistical significance was determined by ANOVA. ***, p < 0.001. B, FLAG-PCTK3 
wild type (WT), S12D, S12A mutants were expressed with Myc-cyclin A2 in COS-7 cells. The cell 
lysates were immunoprecipitated with anti-FLAG antibody (IP: anti-FLAG), and an in vitro kinase 
assay was performed using MBP-Rb C as the substrate. C, GST-PCTK3 wild type (WT), S12D mutant 
and GST-CDK2 was expressed in COS-7 cells with or without FLAG-cyclin A2. The protein 
complexes were pulled down by glutathione-Sepharose beads, and an in vitro kinase assay was 
performed using MBP-Rb C protein as the substrate. The graph shows the average of three 
independent experiments. D, Expression of PCTK3 in HEK293T cells was knocked down by siRNA. 
PCTK3 knockdown cells were treated with 10 µM forskolin at 30 minutes. Cell lysates were 
immunoprecipitated with anti-PCTK3 antibody. Immunoprecipitates were subjected to in vitro kinase 
assay using Rb as the substrate. The activity of endogenous PCTK3 in negative control (NC) 
knockdown cells was taken as 100%. Experiments were performed three times independently. Results 
are expressed as means ± S.E. Statistical significance was determined by ANOVA. *, p < 0.05. E, 
HEK293T cells were transfected with FLAG-PCTK3 wild type and S12D mutant, FLAG-CDK2, and 
FLAG-cyclin A2. After 24 hours, cell extracts were analyzed by immunoblotting with 
anti-phospho-Rb (Ser795), anti-Rb, and anti-FLAG antibodies.  
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5.7. Suppression of PCTK3 Induces Actin Cytoskeletal Change through Phosphorylation of 
Cofilin  
Furthermore, I explored possible physiological functions of PCTK3 using a RNA interference 
approach. I noted that PCTK3 knockdown in HEK293T cells induced morphological changes, cell 
spreading, and extensions (Fig. 11A and B). To investigate whether this is responsible for alteration of 
the actin cytoskeleton, F-actin was visualized by staining cells with phalloidin. Control HEK293T 
cells exhibited a relatively weak cortical distribution of F-actin (Fig. 11B, upper panel). In PCTK3 
knockdown cells, lamellipodial extensions were induced, and F-actin was concentrated at these 
lamellipodia. PCTK3 knockdown also stimulated the appearance of stress fibers (Fig. 11B, lower 
panel). Furthermore, the effects of PCTK3 overexpression on actin filament dynamics were examined. 
Constitutively active mutant of PCTK3 (PCTK3 S12D) suppressed formation of actin stress fibers, 
whereas wild-type PCTK3 and S12A mutant did not. 
Actin filament dynamics are regulated by actin-depolymerizing factor/cofilin proteins, and cofilin 
is inactivated through the phosphorylation at Ser3 [55, 56]. Therefore, I investigated the 
phosphorylation states of cofilin in PCTK3 knockdown HEK293T cells by immunoblotting using 
anti-phospho-cofilin (Ser3). As shown in Fig. 11D, cofilin phosphorylation in PCTK3 knockdown 
HEK293T cells was markedly increased as compared with that in control cells. In contrast, 
overexpression of PCTK3 S12D effectively suppressed cofilin phosphorylation without affecting total 
cofilin protein levels, although wild-type PCTK3 did not affect (Fig. 11E). The phospho-null S12A 
mutant rather slightly increased. These data suggested that PCTK3 was involved in the actin 
cytoskeleton organization. 
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Figure 11. Suppression of PCTK3 induces actin cytoskeletal changes through cofilin 
phosphorylation. A and B, HEK293T cells were transfected with negative control siRNA or PCTK3 
siRNA. After 48 hours, cells were fixed and incubated with Alexa 555-conjugated phalloidin (B, red). 
Hoechst nuclear staining is represented in blue. C, HEK293T cells were transfected with PCTK3 
siRNA for 48 hours and then transfected with FLAG-tagged mouse PCTK3 wild type (WT), S12D or 
S12A mutants. After 24 hours, cells were fixed and incubated with mouse anti-FLAG antibody. The 
primary antibody was visualized with Alexa Fluor 488-conjugated anti-mouse IgG, followed by 
confocal microscopy. Fluorescence for FLAG-PCTK3 (green) and F-actin (Alexa 555-conjugated 
phalloidin staining, red) are shown with merged images (merge is in yellow). Hoechst nuclear staining 
is represented in blue. D, Cell lysates of PCTK3 knock-down HEK293T cells were subjected to 
immunoblotted with anti-PCTK3, anti-cofilin, and anti-phospho-cofilin (Ser3) antibodies. Expression 
of β-actin was used as a loading control. E, HEK293T cells were transfected with FLAG-PCTK3 
(wild-type (WT), S12D or S12A mutant). After 24 hours, cell lysates were subjected to 
immunoblotting using anti-phospho-cofilin (Ser3), anti-cofilin, and anti-FALG antibodies. 
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5.8. PCTK3 Negatively Regulates the FAK and RhoA 
Cofilin phosphorylation is controlled by RhoA/ROCK signaling pathway, which also induces 
stress fiber formation [29]. Thus, I investigated the RhoA and Rac1 activities by using Rhotekin/ or 
PAK RBD pull down methods. As shown Fig. 12A, PCTK3 knockdown led to RhoA activation and 
Rac1 inactivation in HEK293T cells, indicating that PCTK3 regulates the balance between the RhoA 
and Rac1 activities. To gain the insight into the mechanisms of RhoA regulation by PCTK3, I explored 
the signal transduction pathway between PCTK3 and RhoA by using various anti-phospho antibodies. 
As shown in Fig. 12B, immunoblot analysis revealed that phospho-Focal adhesion kinase (FAK) 
(Tyr397) and phospho-Src family (Tyr416) are increased in PCTK3-knockdown cells, while the 
expression level of FAK1 and Src showed no change. In addition, PCTK3-knockdown did not affect 
the phosphorylation of Src at Try527 which is the CSK (C-terminal Src kinase) phosphorylation site, 
indicating that PCTK3 does not implicate the CSK regulation. Interestingly, I observed that 
phosphorylated FAK and phosphorylated Src were co-localized with F-actin at lamellipodia in 
PCTK3-knockdown cells, whereas phosphorylated FAK and phosphorylated Src did not detected in 
control cells (Fig. 12C and 12D). FAK plays a central role in the focal adhesion assembly and 
activating various cytoskeletal-associated proteins including RhoA and Rac1. Taken together, PCTK3 
controls actin cytoskeleton through negatively regulating the FAK and RhoA activities.  
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Figure 12. PCTK3-knockdwon activates the FAK and RhoA activities. A, PCTK3-knockdown cell 
lysates were incubated with Rhotekin/ or PAK-RBD beads. The avtive-RhoA or active-Rac1 bound to 
the beads were subjected to immunoblot analysis using anti-RhoA or anti-Rac1 antibodies. Expression 
of GAPDH was used as a loading control. Relative activity of RhoA and Rac1 were normalized by the 
RhoA or Rac1 levels in total cell lysates. The activity of RhoA and Rac1 in NC siRNA cells were 
taken as 1. Results are expressed as means ± S.E. from three independent experiments. Statistical 
significance was determined by student T test. **, p < 0.01. *, p < 0.05. B, PCTK3-knockdown cell 
lysates were subjected to immunoblot analysis using anti-FAK, anti-Src, anti-phospho-Src (Tyr416), 
anti-phospho-Src (Tyr527), anti-phospho-FAK (Tyr397), and anti-PCTK3 antibodies. Immunoblot 
intensity of GAPDH was used as a loading control. Relative phosphorylation of FAK and Src 
were normalized by the FAK or Src levels in total cell lysates. The phosphorylation of FAK and 
Src in NC siRNA cells were taken as 1. Results are expressed as means ± S.E. from three independent 
experiments. Statistical significance was determined by student T test. **, p < 0.01. *, p < 0.05. C and 
D, PCTK3-knockdown cells were subjected to immunofluorescent staining using anti-phospho-FAK 
(Tyr397) and anti-phospho-Src (Tyr416) antibodies. Fluorescence for phosphor-FAK (Tyr397) and 
anti-phospho-Src (Tyr416) (green) and F-actin (Alexa 555-conjugated phalloidin staining, red) are 
shown with merged images (merge is in yellow). Hoechst nuclear staining is represented in blue. 
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Chapter 6. Discussion 
In this study, these findings provide the information about an activation mechanism of PCTK3, 
which activity is regulated by two step pathway. One step is the binding to cyclin A2, which induce the 
weakly activation of PCTK3. Cyclin A2 enhance the catalytic activity of CDK2 by causes the 
conformational changes in the PSTAIRE helix and T-loop region of the kinase [57]. The kinase 
domain of PCTK is highly conserved between isoforms (more than 80 % similarity) and displays high 
sequence homology with the kinase domain of CDK2 (52 % identity for human PCTK3 and human 
CDK2 kinase domains) [4]. The crystal structure of PCTK3 has been still remained to be determined, 
while that of PCTK1 is available from the Protein Date bank (PDB ID code 3MTL). By comparison 
with the crystal structure of CDK2/cyclin A2 complex and PCTK1, two residues Lys225 and Glu253 of 
cyclin Y have been identified as the important residues for the binding to PCTK1 1 [47]. The Lys–Glu 
pair is found in different cyclins and likely is a conserved structural feature in CDK/cyclin complexes, 
suggesting that PCTK1 is activated by cyclin Y in a manner similar to which cyclin A2 activates 
CDK2. Additionally, although crystal structure analysis of PCTK1 also demonstrated that the 
PCTAIRE sequence forms β-strand instead of helix, it has been reported that the PCTAIRE sequence 
and its peripheral region of PCTK1 are important for the interaction with cyclin Y [9]. Accordingly, 
these results suggest that PCTAIRE sequence of PCTK is important for the binding to cyclins. 
Furthermore, as shown Fig.5C, all of three PCTK isoforms interacted with cyclin A2 with an equal 
affinity, suggesting that cyclin A2 binds to PCTK3 thorough the common region of PCTK isoforms, 
such as the PCTAIRE sequence. On the other hand, Fig.5A showed that PCTK3 is not complex with 
CDK1 and CDK2, that is, PCTK3 is competed with CDK1 and CDK2 for the interaction with cyclin 
A2. Furthermore, I found that binding of cyclin A2 with PCTK3 is weakly than that of with CDK2 in 
the proliferating-cells, suggests that cyclin A2 predominantly binding to CDK2 or CDK1 during cell 
cycle.  
On the other hand, I also observed that cyclin E1 has a greater affinity for PCTK3 than cyclin A2, 
but it was not affected the catalytic activity of PCTK3. The best studied function of cyclin E1 is 
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activated in the late G1 phase of the cell cycle via complex with CDK2 and is implicated to promoting 
S-phase entry [58]. However, recent study has suggested that cyclin E inhibits the activity of CDK5 by 
competing with p35 for CDK5 binding [59]. These results suggest that cyclin E1 inactivates PCTK3 
by dissociating cyclin A2 form PCTk3. In order to obtain the more detail activation mechanism of 
PCTK3 by cyclin A2 and cyclin E1, it would be necessary to perform the crystal structure analysis. 
Although cyclin A2 has no nuclear localization signal (NLS), it shuttles between the nucleus and the 
cytoplasm because of its binding partners [60, 61]. However, the translocation mechanism of cyclin 
A2 remains unrevealed because of the fact that CDK2 also has no NLS signal. Recently, S phase 
cyclin A associated protein residing in the endoplasmic reticulum (SCAPER) was identified and 
characterized as a substrate of cyclin A2/CDK2 which is localized to cytoplasm exclusively [13]. The 
function of SCAPER remains unknown although it was suggested that SCAPER might regulate the 
cell cycle progression and act as buffer the cytoplasmic pool of cyclin A2. PCTK3 is also cytoplasmic 
protein and colocalized with cyclin A2 in the cytoplasm. Furthermore, I observed that PCTK3 bound 
to cyclin A2 in the cytoplasm and promoted the transition of cyclin A2 from nuclear to cytoplasm 
(Fig.6D, Fig.7). These results demonstrated that PCTK3 is the cytoplasmic binding partner of cyclin 
A2 and cyclin A2 alter its subcellular localization by binding to different partners. 
The expression levels of cyclin A2 are tightly controlled by transcription and ubiquitin-mediated 
degradation in a temporal manner. Cyclin A2 begins to be degraded in early prometaphase and is 
completed at metaphase. The major ubiquitin ligase in mitosis is the anaphase-promoting 
complex/cyclosome (APC/C) [53]. However, the proteolysis mechanism of cytoplasmic cyclin A2 is 
still unrevealed. Because the expression levels of cyclin A2 is decreased in PCTK3 knock-down cells, 
I hypothesized that PCTK3 protects cyclin A2 from proteolysis. To verify this hypothesis, I 
investigated the regulation of cyclin A2 degradation. As shown Fig. 8B, although free cyclin A2 is 
readily degraded by the proteasome, degradation of cyclin A2 is suppressed in the presence of PCTK3. 
These observations strongly supported the physiologically significance of the association of PCTK3 
with cyclin A2.  
35 
In addition to activation by binding to cyclin A2, PCTK3 is also activated by PKA via 
phosphorylation at Ser12, which induce further activation of PCTK3. Endogenous PCTK3 is 
phosphorylated and activated by forskolin induced PKA activation in HEK293T cells. Again, point 
mutation analysis also revealed that PKA phosphorylates Ser12, Ser66 and Ser109 of PCTK3 in vitro and 
in vivo. These results demonstrated that PCTK3 is the bona fide substrate of PKA. I also observed that 
the activity of phosphor-mimicked Ser12 is comparative to the activity of CDK2 in the presence of 
cyclin A2, suggesting that not only binding to cyclin A2, but also the phosphorylation at Ser12 of 
PCTK3 is require for the fully activation of PCTK3. Although phospho-mimicked Ser12 cause an 
increase of the PCTK3 activity, phospho-mimicked Ser66 and Ser109 (homologous to Ser119 and Ser153 
of PCTK1, respectively) indicated no effect against the catalytic activity of PCTK3. Recently, 
Mikolcevic et al. also reported that the PKA plays an inhibitory role in interaction between PCTK1 
and cyclin Y by phosphorylation on Ser153 of PCTK1 [9]. Furthermore, phosphorylation at Ser153 of 
PCTK1 also creates the binding motif of 14-3-3 proteins and transfers PCTK1 from the cell membrane 
to cytoplasm [9]. 14-3-3 proteins consist of 7 type isoform and have the ability to interact with various 
proteins [62]. A previous report showed that PCTK3 is interacted with 14-3-3ζ [63]. Consisted with 
this, I found that PCTK3 binds to 14-3-3 β, γ, η, ε, τ and ζ (date not shown). Therefore, 
phosphorylation of Ser66 and Ser109 of PCTK3 may mediate the interaction with 14-3-3 proteins and 
alter the subcellular localization. PKA also involves in the regulation of cellular structure through 
phosphorylates the cytoskeletal proteins including microtubules, intermediate filaments and actin [64, 
65]. Furthermore, PKA regulates the actin filament turnover by modulates the activity of LIM domain 
kinase 1 (Limk1) [66]. Additionally, recent study reported that cyclin A2 also play a role in 
cytoskeletal reorganization via associated with RhoA, a member of the small GTPase family. 
Suppression of cyclin A2 by shRNA showed an increase in cell size and d cortical localization of 
F-actin independent of cell cycle and displays an increased cell migration and invasion [14]. Similary 
with cyclin A2-deficient phenotype, PCTK3 knock-down HEK293T cells display an increase of cell 
size and aggregation of F-actin at edge of cell membrane and increased the autophosphorylation of 
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FAK at Tyr397. Phosphorylation of FAK at Tyr397 is the major event related to the FAK activation. 
Activated FAK transmit the signal to actin cytoskeleton by forming focal adhesion with Src family and 
focal adhesion proteins such as paxillin, vinculin or α-actinin [67]. Because FAK is also interacted 
with GEFs and GAPs, and modulates the GDP/GTP-exchanging activities by phosphorylating their 
tyrosine residues, the balance of Rho small GTPases activities are regulated by FAK [68]. Therefore, 
these data suggest that PCTK3 involves the regulation of the cell morphology, motility via negatively 
modulating the FAL activity. 
Although CDKs were originally identified as enzymes that controlled cell cycle events, some 
members of the CDK family are involved in other cellular processes [69]. For example, CDK5 is not 
considered to play a significant role in cell cycle regulation, however, it has an important function in 
the control of neurogenesis, including neurite outgrowth, axon guidance, and cell migration. CDK5 
activated by neuron-specific regulator p35 inhibits p21-activated kinase 1 (PAK1) activity through 
phosphorylation at Thr212 (Pro–Val–Thr212–Pro–Thr–Arg–Asp) [70]. PAK1, an effector of Rac, has a 
pivotal role in cell morphology and motility via the LIMK/cofilin pathway [71]. Phosphorylation of 
PAK1 by p35/CDK5 is likely to be implicated in the dynamics of the actin cytoskeleton reorganization. 
CDK5 also controls neural migration and focal adhesion assembly via directly phosphorylating focal 
adhesion proteins, such as FAK at Ser732 and paxillin at Ser244 [72, 73]. PCTK3 may also 
phosphorylate focal adhesion proteins, and control actin dynamics. 
In summary, I demonstrated that cyclin A2 is a specific activator of PCTK3, and that 
phosphorylation at Ser12 of PCTK3 significantly enhances its kinase activity in the absence of cyclin 
A2. These findings shed light on the activation mechanism of not only PCTK3 but also other 
uncharacterized members of the CDK family, such as PCTK2. Further investigations will be needed to 
clarify the physiological functions and pathological roles of PCTK3. 
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Background: PCTK3 is an uncharacterized serine/threonine kinase that belongs to the cyclin-dependent kinase family.
Results: The activity of PCTK3 is increased via interaction with cyclin A2 and phosphorylation by PKA. PCTK3 knockdown
induces actin polymerization.
Conclusion: PCTK3 is activated by cyclin A2 and PKA and is involved in actin dynamics.
Significance: This study provides clues to the physiological function of PCTK3.
PCTAIRE kinase 3 (PCTK3)/cyclin-dependent kinase 18
(CDK18) is an uncharacterized member of the CDK family
because its activator(s) remains unidentified. Here we describe
the mechanisms of catalytic activation of PCTK3 by cyclin A2
and cAMP-dependent protein kinase (PKA). Using a pulldown
experiment with HEK293T cells, cyclin A2 and cyclin E1 were
identified as proteins that interacted with PCTK3. An in vitro
kinase assay using retinoblastoma protein as the substrate
showed that PCTK3 was specifically activated by cyclin A2 but
not by cyclin E1, although its activity was lower than that of
CDK2. Furthermore, immunocytochemistry analysis showed
that PCTK3 colocalized with cyclin A2 in the cytoplasm and
regulated cyclin A2 stability. Amino acid sequence analysis
revealed that PCTK3 contained four putative PKA phosphory-
lation sites. In vitro and in vivo kinase assays showed that
PCTK3 was phosphorylated by PKA at Ser12, Ser66, and Ser109
and that PCTK3 activity significantly increased via phosphoryl-
ation at Ser12 by PKA even in the absence of cyclin A2. In the
presence of cyclin A2, PCTK3 activity was comparable to CDK2
activity. We also found that PCTK3 knockdown in HEK293T
cells induced polymerized actin accumulation in peripheral
areas and cofilin phosphorylation. Taken together, our results
provide the first evidence for the mechanisms of catalytic acti-
vation of PCTK3by cyclinA2 andPKAand aphysiological func-
tion of PCTK3.
Inmammals, the cyclin-dependent kinases (CDKs),2 a family
of serine/threonine protein kinases, play an important role in
regulating cellular functions such as cell proliferation, tran-
scription, and neuron function (1). Their activities are regu-
lated by associationswith different cyclins and phosphorylation
at specific sites by protein kinases (2). Because cyclins are dif-
ferentially expressed and degraded by ubiquitin-mediated pro-
teolysis at specific cell cycle phases, CDK activity oscillates dur-
ing cell cycle transitions (3). Canonical CDKs contain the
PSTAIREhelix, which has been implicated in binding to cyclins in
the kinase domain (4). The PCTAIRE kinase (PCTK) subfamily of
CDKs includes threemembers, PCTK1/CDK16, PCTK2/CDK17,
and PCTK3/CDK18, which contain the PCTAIRE sequence
instead of the PSTAIRE sequence. PCTK family members have
high sequence homology in their central kinase domains,
whereas the structures of their N-terminal and C-terminal
regions differ. PCTK genes are conserved in higher eukaryotes,
fromCaenorhabditis elegans to humans. However, there are no
PCTK orthologs in yeast. The PCTK subfamily is widely
expressed in mammalian tissues and is relatively more abun-
dant in post-mitotic cells, suggesting that they may function in
higher eukaryotes and have different biological functions from
those during the cell cycle (5). PCTK1 is the best-characterized
member of this kinase family and regulates neurite outgrowth
in theNeuro2Aneuroblastoma cell line (6). It is also involved in
membrane trafficking through the early secretory pathway via
phosphorylation of N-ethylmaleimide-sensitive fusion protein
(7, 8). A recent study reported that PCT-1, the C. elegans
ortholog of PCTK1, is complexed with CYY-1 (ortholog of
mammalian cyclin Y, a novel membrane-associated cyclin) and
is also necessary for targeting presynaptic components to the
axons (9). Furthermore, human PCTK1 is activated by cyclin Y
and is essential for spermatogenesis (10). PCTK2 is associated
with Trap (tudor repeat associator with PCTAIRE 2) and ik3–
1/cables, an adaptor that functionally connects c-abl andCDK5
to support neurite growth (11, 12). The third member of this
family, PCTK3, has been the least studied. Although exoge-
nously expressed PCTK1 and PCTK2 phosphorylate myelin
basic protein and histoneH1 in vitro, PCTK3 kinase activity has
not been detected. To characterize PCTK3 activity and eluci-
* This work was supported in part by a grant-in-aid for Scientific Research
from theMinistry of Education, Culture, Sports, Science, andTechnologyof
Japan (to K. Y.).
1 To whom correspondence should be addressed. Fax: 81-88-655-3161;
E-mail: yuasa@bio.tokushima-u.ac.jp or kyuasa@tokushima-u.ac.jp.
2 The abbreviations used are: CDK, cyclin-dependent kinase; PCTK, PCTAIRE
kinase; PFTK, PFTAIRE kinase; PKA, protein kinase A; Rb, retinoblastoma
protein; MBP, maltose-binding protein; MyBP, myelin basic protein; PAK1,
p21-activated kinase 1; SCAPER, S phase cyclin A-associated protein resid-
ing in the endoplasmic reticulum.
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date its regulatorymechanism, it is necessary to identify activa-
tors for PCTK3.
Mammalian cyclin A consists of two isoforms: cyclin A1 and
cyclin A2. In male mice, cyclin A1 is predominantly expressed
in germ cells and is required for the entry of germ cells into the
first meiotic division (13). In contrast, cyclin A2 is ubiquitously
expressed in somatic cells and has a major role in S-phase pro-
gression and theG2/Mphase transition by activatingCDK2 and
CDK1, respectively. Although cyclin A is predominantly local-
ized in the nucleus during S phase, it also shuttles between the
nucleus and cytoplasm and is degraded by ubiquitin-mediated
proteolysis during the G2 phase. Cyclin A/CDK2 is transiently
maintained by SCAPER (S phase cyclin A-associated protein
residing in the endoplasmic reticulum), an S phase cyclin A-as-
sociated protein, in the cytoplasm (14). However, a recent study
showed cyclin A2 is involved in the regulation of cell migration
and invasiveness through its direct interaction with RhoA, sug-
gesting a novel function of cyclin A in a CDK1- and CDK2-
independent manner (15).
Protein kinase A (PKA) phosphorylates numerous proteins
involved in various cellular phenomena and preferentially to
phosphorylates a serine or threonine within the following con-
sensus sequence: Arg-Arg-X-Ser/Thr (X represents any amino
acid) (16). PKA also plays an important role in maintaining
meiotic arrest (17). In Xenopus oocytes, PKA phosphorylates
and inactivates Cdc25C phosphatase, whereas Wee1B kinase
activity is enhanced by PKA (18, 19). The activity of the cyclin
B-CDK1 complex is controlled by Wee1 kinase and Cdc25C
phosphatase (20, 21). PKA regulates the activity of the cyclin
B-CDK1 complex via dual regulation of the Cdc25 phosphatase
and Wee1B kinase (18). On the other hand, PKA inhibits the
interaction between PCTK1 and cyclin Y via phosphorylation
of PCTK1 at Ser153, resulting in PCTK1 inactivation (6, 10).
Thus, PKA regulates the activities of CDKs in either a direct or
an indirect manner.
In this study we demonstrated that PCTK3 is activated by its
association with cyclin A2 and phosphorylates retinoblastoma
protein (Rb) in vitro. In addition, we found that PCTK3 con-
tains four putative PKA phosphorylation sites (Arg-Arg-X-Ser/
Thr) and that PCTK3 phosphorylation by PKA results in an
increase in its catalytic activity even in the absence of cyclin A2.
These findings provide some insights into the functions of
PCTK3.
EXPERIMENTAL PROCEDURES
Antibodies and Materials—Antibody against cyclin A was
purchased from BD Biosciences, and anti-cyclin B1, anti-cyclin
D1, anti- cyclin E1, anti-cyclin E2, anti-cyclin H, anti-CDK1,
anti-CDK2, anti-Rb, anti-phospho-Rb (Ser795) and (Ser807/811),
anti-cofilin, anti-phospho-cofilin (Ser3), and anti-phospho-
PKA substrate (RRX(S/T)) antibodies were from Cell Signaling
Technology. Anti-PCTK3, anti--tubulin, and anti--actin
antibodies were from Santa Cruz Biotechnology. Anti-FLAG
M2 antibody was form Sigma. Anti-GST antibody was from
Wako Pure Chemical Industries. Anti-Strep antibody was
from Qiagen. Alexa-555 conjugated-phalloidin was from
Cytoskeleton.
Plasmid Construction—cDNAs encoding mouse full-length
PCTK1, PCTK2, PCTK3, CDK2, PFTAIRE kinase 1 (PFTK1),
cyclin A2, cyclin E1, cyclin K, and cyclin Y and human retino-
blastoma protein (779–928 amino acid; Rb C) were cloned by
PCR using the respective specific primers. PCR products were
cloned into TA-cloning vector pGEM-T Easy (Promega), and
the insertedDNA sequences were confirmed byDNA sequenc-
ing. The inserted DNAs were subcloned in-frame into the dif-
ferent mammalian expression vectors including Strep-tagged
expression vector pEXPR-IBA105 (IBA GmbH), glutathione
S-transferase (GST) fusion expression vector pEBG, and
FLAG-tagged expression vector pFLAG-CMV-2 (Sigma). A
cDNA encoding for human RbCwas subcloned into the pMAL
vector (New England Biolabs) of the bacterial maltose-binding
protein (MBP) fusion expression system. The expression plas-
mid pFLAG-PKA-C encoding the catalytic subunit isoformof
mouse PKA was described previously (22). Site-directed
mutagenesis was performed using PrimeSTAR Mutagenesis
Basal Kit (Takara Bio) according to themanufacturer’s instruc-
tions. The mutation was confirmed by DNA sequencing
analysis.
Expression and Purification of Rb Recombinant Protein—The
bacterial expression plasmid of Rb, pMAL-Rb C, was intro-
duced into the bacterial strain BL21 Star DE3 (Invitrogen). An
overnight culture in LB medium was diluted in fresh LB
medium and incubated at 37 °C for 1 h with continuous shak-
ing. After isopropyl-1-thio--D-galactopyranoside was added
to the culture to a final concentration of 0.2mM, the culturewas
incubated at 30 °C for an additional 6 h. The cells were resus-
pended in ice-cold extraction buffer A (20 mM Tris-HCl, pH
8.0, 1 mM EDTA, 10 g/ml aprotinin, and 10 g/ml leupeptin).
After freezing and thawing, suspended cells were sonicated on
ice in short bursts. The lysate was cleared by centrifugation at
10,000 g for 10 min at 4 °C. The supernatant was then incu-
bated with amylose resin (New England Biolabs) overnight at
4 °C. The beads were washed 5 times with ice-cold extraction
buffer A and incubated with 10 mM maltose at 4 °C to elute
fusion protein from the beads. After centrifugation, the super-
natant was dialyzed against PBS. The purified protein was
electrophoresed on SDS-PAGE and visualized by Coomassie
Brilliant Blue staining, and the protein concentration was
determined by Bradford assay (Bio-Rad) using BSA as a
standard.
Cell Culture andTransfection—COS-7, HeLa, andHEK293T
cells were cultured inDulbecco’smodified Eagle’smedium sup-
plemented with 10% FBS, 100 units/ml penicillin, and 100
g/ml streptomycin at 37 °C in 5% CO2. Cells were transfected
with various expression vectors using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Subcellular Fractionations—HEK293T cells were washed
twice with ice-cold PBS, harvested by scraping, and lysed in a
buffer A (10 mMHEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 10
g/ml leupeptin, and 10 g/ml aprotinin). After incubation on
ice for 15min, the cells weremixedwith 0.5%Nonidet P-40 and
homogenized by vortex for 10 s. The homogenate was centri-
fuged at 2500 rpm for 3 min to sediment the nuclei. The super-
natant was then centrifuged at a 10,000 rpm for 10min, and the
resulting supernatant was used as the cytoplasm fraction. The
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nuclear pellet was washed three times with buffer A to remove
any contamination from cytoplasmic proteins. To extract
nuclear proteins, the isolated nuclei were resuspended in buffer
B (20mMHEPES, pH 7.9, 400mMNaCl, 1 mM EDTA, 10g/ml
leupeptin, and 10 g/ml aprotinin), and the mixture was incu-
bated on ice for 20 min. Nuclear lysates were collected after
centrifugation at 12,000 rpm for 15 min at 4 °C. The purity of
nuclear and cytoplasm fractions was confirmed by immuno-
blotting using an anti-lamin B1 antibody (MBL) as a nuclear
marker and -tubulin antibody as a cytoplasmic marker,
respectively.
Pulldown and Co-immunoprecipitation Assays—Pulldown
and co-immunoprecipitation assays were performed as previ-
ously described (23). Briefly, cells were scraped in an ice-cold
TNE buffer (20 mMTris-HCl, pH 7.5, 150mMNaCl, 0.5%Non-
idet P-40, and 1mM EDTA) supplemented with protease inhib-
itors (10 g/ml leupeptin and 10 g/ml aprotinin). The cell
extracts were centrifuged at 10,000  g for 10 min at 4 °C
before immunoprecipitation or immunoblotting. Equal protein
amounts of the lysates were analyzed for protein expression.
For pulldown assays, lysates were incubated with Strep-Tactin
Sepharose (IBA GmbH) or glutathione Sepharose (GE Health-
care) overnight at 4 °C. For immunoprecipitation, lysates were
incubated with anti-FLAG M2 or anti-PCTK3 antibody in the
presence of protein G Sepharose (GE Healthcare) overnight at
4 °C. The beads were washed 4 times with wash buffer (20 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Nonidet P-40, and 1 mM
EDTA). Precipitated proteins were subjected to in vitro kinase
assay or immunoblot analysis. Protein expression and phos-
phorylation were determined by immunoblotting of immuno-
precipitates or total cell lysates.
Transfection of Small Interference RNA—The synthetic small
interfering RNA (siRNA) oligonucleotides for PCTK3 (PCTK3
siRNA#1 (ID# SASI_Hs02_00334101), PCTK3 siRNA#2 (ID#
SASI_Hs01_00015477), and PCTK3 siRNA#3 (ID# SASI_
Hs02_00374212)) were purchased from Sigma. A MISSION
siRNA Universal Negative Control #1 was used as the negative
control. The transfection of siRNA was performed using Lipo-
fectamine 2000 according to the manufacturer’s instructions.
In Vitro Kinase Assay—In vitro kinase assays were carried out
as previously described (23). For in vitro kinase assay of PCTK3,
cell lysates were incubated with a glutathione-Sepharose or
immunoprecipitated with anti-PCTK3 antibody and protein G
Sepharose overnight at 4 °C by rotation. The beads were
washed 3 times with wash buffer and twice with 50 mM Tris-
HCl, pH 7.5. The kinase reaction was carried out by resuspend-
ing the complexes in 100 l of kinase buffer (50 mM Tris-HCl,
pH 7.5, 20 mMmagnesium acetate, 20 or 50 MATP and phos-
phatase inhibitor mixture (Nacalai Tesque)) including 5 g/ml
purified MBP-Rb C in the absence or presence of 2 Ci of
[-32P]ATP and incubating for 30min at 30 °C. Phosphorylated
MBP-Rb C was separated by SDS-PAGE and visualized with a
BAS-1500 Bioimaging Analyzer (Fuji Film) or subjected to
immunoblot analysis using anti-phospho-Rb (Ser795) antibody.
To assay the phosphorylation of PCTK3 by PKA, cell lysate
were immunoprecipitated with anti-FLAG antibody overnight
at 4 °C by rotation. The kinase reaction was carried out by
resuspending the complexes in 100 l of kinase buffer with 2
Ci [-32P]ATP and incubating for 30 min at 30 °C. Immuno-
complexes were released by heating at 95 °C in SDS sample
buffer and subjected to SDS-PAGE, and phosphorylated pro-
teinswere visualized by BAS-1500 BioimagingAnalyzer. Quan-
titative densitometric analysis was performed using Image J
software.
In Vivo Kinase Assay—HEK293T cells were treated with
10 M forskolin for 30 min in the presence of 10% FBS and
scraped in an ice-coldTNEbuffer supplementedwith phospha-
tase inhibitor mixture. The cell extracts were centrifuged at
10,000 g for 10 min at 4 °C to remove cellular debris, and the
supernatants were immunoprecipitated with anti-PCTK3 anti-
body with protein G-Sepharose overnight at 4 °C by rotation.
The beads were washed with wash buffer, and immunocom-
plexes were released by heating at 95 °C in SDS sample buffer,
subjected to SDS-PAGE, and immunoblotted using anti-phos-
pho-RRX(S/T) antibody.
Immunofluorescence Analysis—Immunofluorescence analy-
sis was performed as previously described (23). In brief,
HEK293T cells grown on poly-L-lysine-coated chamber slides
were cotransfected with Myc-cyclin A2 together with either
FLAG-PCTK3 or FLAG-CDK2. At 24 h post-transfection, cells
were washed twice with PBS and fixed for 20min in 3.7% form-
aldehyde. After sequential washing with PBS, cells were per-
meabilized for 5min in 0.1%TritonX-100, washed 3 times with
PBS, and then treated with 5% BSA for 30 min. Cells were sub-
sequently incubated with mouse anti-FLAG M2 IgG or rabbit
anti-Myc polyclonal antibody overnight at 4 °C. After 3 washes
with PBS, cells were incubated for 1 hwith goat anti-mouse IgG
directly conjugated to Alexa Fluor 488 or goat anti-rabbit IgG
directly conjugated to Alexa Fluor 555 (Invitrogen). The slides
were washed thoroughly with PBS and mounted in fluorescent
mountingmediumVectashield (Vector Laboratories). A confo-
cal laser-scanning microscope (Leica TCS-SP5) was used to
obtain staining profiles.
RESULTS
Identification of Cyclin A2 as An Activator of PCTK3—
PCTK1, amember of the PCTK subfamily, is activated bymem-
brane-associated cyclin Y (10, 24). We hypothesized that
PCTK3 was also activated by cyclin family members. To iden-
tify PCTK3 activators, we expressed Strep-tagged mouse
PCTK3 in HEK293T cells and conducted Strep pulldown
experiments. The proteins that coprecipitated with PCTK3
were analyzed by immunoblot assay using anti-cyclinA, B1,D1,
E1, E2, and H antibodies. Immunoblot analysis revealed that
PCTK3 interacted with cyclin A and cyclin E1, but not cyclin
B1, D1, E2, or H, in HEK293T cells (Fig. 1A). To confirm the
interaction between PCTK3 and cyclin A2 or E1, we performed
GST pulldown experiments using lysates prepared fromCOS-7
cells expressing GST-fused PCTK3 and FLAG-tagged cyclins.
We also examined whether cyclin K and cyclin Y bound to
PCTK3, because PCTK3 was found to interact with cyclin K in
a large-scale interaction study (25). As shown in Fig. 1B, GST-
PCTK3 associated with FLAG-cyclin A2 and cyclin E1 but not
with cyclin K or cyclin Y.
Subsequently, to determinewhether PCTK3 activitywas reg-
ulated by binding to cyclin A2 or cyclin E1, we performed an in
Mechanism of PCTK3/CDK18 Activation
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vitro kinase assay using retinoblastoma protein (Rb) as the sub-
strate. Rb is phosphorylated by some CDKs in a cell cycle-de-
pendent manner, and PFTK1, which is activated by cyclin D3
and cyclin Y, also phosphorylates Rb (26, 27). TheC terminus of
Rb contains a cluster of seven candidate CDK phosphorylation
sites (Ser/Thr-Pro motifs: Ser780, Ser788, Ser795, Ser807, Ser811,
Thr821, and Thr826) (28). For this in vitro kinase assay, we pro-
duced recombinantMBP-fused Rb C (amino acids 779–928) in
Escherichia coli. COS-7 cells were cotransfected with GST-
PCTK3 in the presence or absence of FLAG-cyclin A2 or E1,
after which cell lysates were subjected to glutathione-Sephar-
ose pulldown. In an in vitro kinase analysis with [-32P]ATP,
MBP-Rb C was phosphorylated by PCTK3 in the presence of
cyclin A2, whereas cyclin E1 did not activate PCTK3 (Fig. 1C).
We also performed an in vitro kinase assay using myelin basic
protein (MyBP) and histone H1 as substrates. As shown in Fig.
1D, cyclinA2-CDK2 complex strongly phosphorylated all three
of the substrates tested (Rb, MyBP, and histone H1). However,
the catalytic activity of PCTK3 was much lower than that of
CDK2 even in the presence of cyclin A2. Among the three sub-
FIGURE 1. Identification of cyclin A2 as an activator of PCTK3. A, HEK293T cells were transfected with Strep-PCTK3. After the Strep pulldown assay, the
precipitated proteins were subjected to immunoblot analysis with anti-cyclin A, anti-cyclin B1, anti-cyclin D3, anti-cyclin E1, anti-cyclin E2, and anti-cyclin H
antibodies. Total cell lysates were used as the input samples and positive control. B, GST-PCTK3 was expressed in COS-7 cells with either FLAG-cyclin A2,
FLAG-cyclin E1, FLAG-cyclin K, or FLAG-cyclin Y. In the control experiment (GST-PCTK3 ()), GST alonewas expressed instead of GST-PCTK3. The GST pulldown
precipitateswere immunoblottedwith anti-FLAGantibody. Protein expressionwas confirmedby immunoblotting total cell lysates.C, GST andGST-PCTK3was
expressed with either FLAG-cyclin A2 or FLAG-cyclin E1 in COS-7 cells. After the GST pulldown, the precipitated samples were incubated in a kinase buffer
containing [-32P]ATP and MBP-Rb C for 30 min. The supernatants containing MBP-Rb C were separated on SDS-PAGE, after which the gel was analyzed by
bioimaging analyzer. The expression level of GST-fused and FLAG-tagged proteins was confirmed by immunoblotting with anti-FLAG and anti-GST antibody,
respectively. D, COS-7 cells were transfected with Strep-PCTK3 and FLAG-cyclin A2. GST pull downed proteins were incubated in a kinase buffer containing
MBP-Rb C for 30 min. The precipitates and supernatants were analyzed by SDS-PAGE and immunoblotting with anti-FLAG and anti-phospho-Rb (Ser795) and
(Ser807/811) antibodies, respectively. D, COS-7 cells were transfected with Strep-PCTK3, Strep-CDK2, and FLAG-cyclin A2. Strep pull-downed proteins were
incubated in a kinase buffer containingMyBP, MBP-Rb C, or histone H1 for 30min. The supernatants were analyzed by SDS-PAGE and bioimaging analyzer. IB,
immunoblot. E, Strep-PCTK3 was expressed in COS7 cells with FLAG-cyclin A2. After the Strep pulldown, bound proteins were incubated in a kinase buffer
containing MBP-Rb C for 30 min. The precipitates and supernatants were analyzed by SDS-PAGE and immunoblotting with anti-FLAG and anti-phospho-Rb
(Ser795) and (Ser807/811) antibodies, respectively. CBB, Coomassie Brilliant Blue.
Mechanism of PCTK3/CDK18 Activation
18390 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 26•JUNE 27, 2014
 at TO
K
U
SH
IM
A
 U
N
IV
 (KIN/ACC) on February 8, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
strates tested, Rb was the most efficiently phosphorylated
by cyclin A2-PCTK3 complex. In addition, phosphorylated
MBP-Rb C was detected using antibodies against phospho-Rb
(Ser795) and phospho-Rb (Ser807/811) (Fig. 1E). Both of these
antibodies detected Rb phosphorylation only when PCTK3 and
cyclin A2 were cotransfected, indicating that cyclin A2-PCTK3
complex phosphorylates Rb at least at Ser795 and Ser807/811 in
vitro. These results showed that PCTK3 is activated through its
association with cyclin A2.
Cyclin A2 Specifically Activates PCTK3—Cyclin A2 interacts
with CDK1 and CDK2 during cell cycle progression (29). We
performed GST pulldown experiments to evaluate whether Rb
phosphorylation was dependent on PCTK3 or other kinases
that coprecipitated with cyclin A2. As shown in Fig. 2A, endog-
enous CDK1 and CDK2 were specifically coprecipitated with
GST-cyclin A (lane 4), whereas GST-PCTK3, GST-PCTK3/
FLAG-cyclin A2 complex, and FLAG-cyclin A2 did not copre-
cipitatewith endogenousCDK1 andCDK2 (lanes 1–3). In addi-
tion, we designed a PCTK3 inactive mutant on the basis of
amino acids that are conserved among various members of the
CDK family. An analogous K194R mutation at the putative
ATP binding site of PCTK1 generates a kinase deadmutant (6).
We created a kinase-deadmutant of PCTK3, inwhich the puta-
tiveATPbinding sitewas replaced by arginine (PCTK3K150R),
and evaluated its catalytic activity with an in vitro kinase assay.
Although both PCTK3 wild type and K150R interacted with
cyclinA2, no kinase activity of PCTK3K150Rwas detected (Fig.
2B). Thus, Rb phosphorylation is dependent on PCTK3 but not
on other protein kinases, and it is highly likely that cyclin A2 is
an activator of PCTK3.
We also examinedwhether othermembers of the PCTK sub-
family, PCTK1 and PCTK2, were activated by cyclin A2,
because PCTK2 activators have not yet been identified.
Although PCTK1 and PCTK2 interacted with cyclin A2, only
PCTK3 was activated by cyclin A2 (Fig. 2C). In contrast,
PFTK1, with high homology to PCTK3, was not associatedwith
cyclin A2 and did not phosphorylate Rb C (Fig. 2D). However,
GST pulldown and in vitro kinase assays suggested that CDK2
had a higher affinity for cyclin A2 than PCTK3 and that the
catalytic activity of PCTK3 was lower than that of CDK2 in the
presence of cyclin A2 (Fig. 2D). These results demonstrated
that cyclin A2 specifically activates PCTK3 and suggested that
there are additional mechanisms for PCTK3 activation in addi-
tion to its interaction with cyclin A2.
FIGURE 2. Cyclin A2 specifically activates PCTK3. A, COS-7 cells were transfected with GST-PCTK3, FLAG-cyclin A2, and GST-cyclin A2. In the control
experiment, GST alone was transfected instead of GST-PCTK3 or GST-cyclin A2. The GST pulldown precipitates were subjected to immunoblotting with
anti-FLAG, anti-CDK1, and anti-CDK2 antibodies. B, GST-PCTK3wild type (WT) or K150Rmutantwas expressed in COS-7 cellswith FLAG-cyclin A2. In the control
experiment, GST alonewas expressed instead of GST-PCTK3. After theGSTpulldown, the boundproteinswere incubated in a kinase bufferwithMBP-RbC. The
precipitates and supernatants were analyzed by SDS-PAGE and immunoblotting with anti-FLAG and anti-phospho-Rb (Ser795) antibodies, respectively. C,
FLAG-cyclin A2was expressed in COS-7 cells with GST, GST-PCTK1, GST-PCTK2, or GST-PCTK3. The GST pulldown precipitates were subjected to in vitro kinase
assay using anti-phospho-Rb (Ser795) antibody. D, GST, GST-PCTK3, GST-PFTK1, or GST-CDK2 was expressed in COS-7 cells with FLAG-cyclin A2. The GST
pulled-down proteins were subjected to an in vitro kinase assay.
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Endogenous Interaction between PCTK3 and Cyclin A in the
Cytoplasm—Next, we investigated the endogenous interaction
between PCTK3 and cyclin A. A previous study reported that
PCTK3 protein is expressed in some cell lines including
HEK293 cells (7). Thus, we confirmed whether PCTK3 expres-
sion was detectable in some cell lines. As shown in Fig. 3A, an
anti-PCTK3 antibody detected a specific protein band with the
predictedmolecularmass of PCTK3 inHEK293T cells, whereas
its expression was very low or absent in human breast carci-
noma MCF7cells and human cervical carcinoma HeLa cells.
We confirmed PCTK3 expression in HEK293T cells by knock-
down analysis using siRNA. As shown in Fig. 3B, PCTK3
expression was efficiently reduced by each of the three PCTK3
siRNAs used, whereas negative control siRNA had no effect on
PCTK3 expression.We also examined the subcellular distribu-
tions of PCTK3 and cyclin A by simple cell fractionation.
PCTK3 protein was found in the cytoplasm, whereas cyclin A
was localized in both the cytoplasm and nucleus (Fig. 3C). Sub-
sequently, we investigated cyclin A binding to PCTK3 in the
nuclear and cytoplasmic fractions. Immunoprecipitates from
each fraction with an anti-PCTK3 antibody were analyzed by
immunoblotting with anti-cyclin A antibody. Cyclin A was
detected in the cytoplasmic PCTK3 immunoprecipitates but
not in the nuclear immunoprecipitates (Fig. 3D), indicating that
PCTK3 indeed interacts with cyclinA in vivo.Wealso examined
the intracellular localization of endogenous PCTK3 and cyclin A
in HEK293T cells. Immunofluorescence analysis using confocal
laser-scanning microscopy revealed that PCTK3 and cyclin A
weremainly found in the cytoplasmandnucleus, respectively, and
that they colocalized in the cytoplasm (Fig. 3E).
Additionally, we transfected HEK293T cells with FLAG-
PCTK3 and Myc-cyclin A2 and performed immunofluores-
cence analysis. In cells that were singly transfected with either
Myc-cyclin A2 or FLAG-PCTK3, cyclin A2 was strongly
detected in the nucleus and moderately in the cytoplasm,
whereas PCTK3 was found in only the cytoplasm (data not
shown), consistent with previous data (30). In cells cotrans-
fected with Myc-cyclin A2 and FLAG-PCTK3, cyclin A2 was
translocated from the nucleus to the cytoplasm and colocalized
with PCTK3 in the cytoplasm (Fig. 4, A and C). By comparison,
when cyclin A2 was cotransfected with CDK2, it colocalized
with CDK2 in the nucleus (Fig. 4, B and C). These findings
suggested that PCTK3 and CDK2 regulate the localization of
cyclin A2 in the cytoplasm and the nucleus, respectively.
FIGURE 3. Endogenous interactionbetweenPCTK3and cyclinA in the cytoplasm.A, immunoblot analysis of total proteins prepared fromHeLa,MCF7, and
HEK293T human cell lines. -Actin was used as a loading control. B, siRNA knockdown of PCTK3 in HEK293T cells. Cells were transfected with three different
siRNAs against PCTK3 (#1–3) or negative control siRNA (NC). Forty-eight hours after transfection, cell extracts were immunoblotted with anti-PCTK3 antibody.
Expression of -actin was used as a loading control. C, subcellular distributions of endogenous PCTK3 and cyclin A. HEK293T cells were separated into nuclear
and cytoplasmic fractions as described under “Experimental Procedures.” Aliquots of each fraction were immunoblotted for PCTK3 and cyclin A. The purity of
nuclear and cytoplasmic fractions was confirmed using anti-lamin B1 antibody as a nuclear marker and -tubulin antibody as a cytoplasmic marker, respec-
tively.D, endogenous interaction between PCTK3 and cyclin A in HEK293T cells. The fractionated lysates fromHEK293T cells were immunoprecipitated (IP) using
anti-PCTK3 antibody. The immunoprecipitates were analyzed by immunoblotting with anti-cyclin A antibody. Normal rabbit IgG (IgG) was used as a control. E,
intracellular localization of endogenous PCTK3. HEK293T cells were fixed and incubated with rabbit anti-PCTK3 and mouse anti-cyclin A antibodies. The primary
antibodywas visualizedwith Alexa Fluor 488-conjugated anti-rabbit IgG andAlexa Fluor 555-conjugated anti-mouse IgG followedby confocalmicroscopy. Fluores-
cence for PCTK3 (green) and cyclin A (red) is shownwith themerged images (merge is in yellow). Hoechst nuclear staining is represented in blue.
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PCTK3 Protects Cyclin A2 against Degradation in the
Cytoplasm—Cyclin A2 is degraded during prometaphase by
anaphase-promoting complex/cyclosome (APC/C), and this
degradation is necessary for mitosis progression (31). Cyclin E
bound to CDK2 is also protected from degradation by the pro-
teasome (32). We hypothesized that cyclin A2 interacted with
PCTK3 is also protected from degradation in the cytoplasm.
Thus, to analyze whether PCTK3 regulates cyclin A2 stability,
we investigated the protein levels of cyclinA2 in PCTK3 knock-
down HEK293T cells. As expected, the protein levels of cyclin
A2 in PCTK3 knockdown cells was low compared with that in
negative control siRNA-treated cells (Fig. 5A). To verify the
protective effect of PCTK3 against cyclin A2 degradation,
HEK293T cells cotransfected with FLAG-cyclin A2 and GST-
PCTK3 were treated with cycloheximide, a protein synthesis
inhibitor, after which they were harvested at the indicated
times. Cycloheximide chase analysis showed that cyclin A2 was
rapidly degraded in the absence ofGST-PCTK3, whereas cyclin
A2 degradation was remarkably delayed in the presence of
GST-PCTK3 (Fig. 5B). Furthermore, we examined if PCTK3
sequesters cyclin A2 in the cytoplasm and negatively regulates
CDK2 activity in the nucleus. Nuclear fractions of HEK293T
cells transfected with FLAG-PCTK3were immunoprecipitated
using anti-CDK2 antibody, and an in vitro kinase assay was
performed using Rb as the substrate. As shown in Fig. 5C,
PCTK3 did not regulate CDK2 activity in the nucleus. These
results suggest that PCTK3 may regulate the stability of cyclin
A2, which is normally degraded in the cytoplasm by ubiquitin-
proteasome pathway.
PCTK3 Is Phosphorylated by PKA in Vitro and in Vivo—PKA
is an essential factor that has been implicated in various physi-
ological functions, including cytoskeletal organization, cell
motility, and signal transduction (16). PKA preferentially phos-
phorylates serine/threonine residues within the consensus
sequenceArg-Arg-X-Ser/Thr. A previous report demonstrated
that PKA inactivates PCTK1 via phosphorylation at Ser153 (6).
Amino acid sequence analysis revealed that mouse and human
PCTK3 each contained four putative PKA phosphorylation
sites, RRLS12, RRFS66, RRAS109, and RRQS449 in mouse and
RRFS14, RRFS89, RRAS162, and RRQS502 in human. This sug-
gested that PCTK3 is a substrate for PKA. To determine
whether endogenous PCTK3 was phosphorylated by PKA,
HEK293T cells were treated with the adenylate cyclase activa-
tor forskolin.We immunoprecipitated cell lysates with an anti-
PCTK3 antibody, and followed it by immunoblot analysis using
an anti-phospho-RRX(S/T) antibody. As shown in Fig. 6A,
PCTK3 proteins were specifically precipitated by the anti-
PCTK3 antibody and were efficiently phosphorylated after
treatment with forskolin. Next, we examined whether PKA
directly phosphorylates PCTK3. COS-7 cells were cotrans-
fected with FLAG-PCTK3 and FLAG-PKA catalytic subunit,
after which an in vitro kinase assay was performed. As shown in
Fig. 6B, PKA directly phosphorylated PCTK3. Furthermore, to
identify the PKA phosphorylation sites of PCTK3, we con-
structed four non-phosphorylatable mutants of mouse PCTK3
in which each of the putative PKA phosphorylation sites was
replaced by alanine: S12A, S66A, S109A, and S449A.We tested
these using in vitro and in vivo kinase assays. Phosphorylation
of the S12A, S66A, and S109A mutants was reduced as com-
pared with that of wild type PCTK3, whereas the phosphoryla-
tion intensity of the S449A mutant was almost equal to that of
wild-type PCTK3 (Fig. 6B). Although PKA phosphorylated the
S12A/S66A, S66A/S109A, and S12A/S109Amutants of PCTK3
(Fig. 6C), it failed to phosphorylate the S12A/S66A/S109A
mutant (Fig. 6, B and C). These results identified three serine
residues, Ser12, Ser66, and Ser109, as possible PKA phosphory-
lation sites formousePCTK3.Furthermore, thePKAphosphor-
ylation sites of PCTK3 were confirmed by an in vivo kinase
assay using an anti-phospho-RRX(S/T) antibody. HeLa cells
transiently transfected with FLAG-tagged PCTK3 were treated
with 10 M forskolin. Cell lysates were immunoprecipitated
with an anti-FLAG antibody and then immunoblotted with an
anti-phospho-RRX(S/T) antibody. As expected, forskolin treat-
ment resulted in a 1.7-fold increase in phosphorylation of
FIGURE 4. Different intracellular localization of cyclin A2 in PCTK3- and CDK2-overexpressed cells. A and B, HEK293T cells were cotransfected with
Myc-cyclinA2 togetherwitheither FLAG-PCTK3 (A) or FLAG-CDK2 (B). Cellswere fixedand incubatedwithmouseanti-FLAGand rabbit anti-Mycantibodies. The
primary antibody was visualized with Alexa Fluor 488-conjugated anti-mouse IgG and Alexa Fluor 555-conjugated anti-rabbit IgG followed by confocal
microscopy. Fluorescence for FLAG-PCTK3or FLAG-CDK2 (green) andMyc-cyclinA2 (red) is shownwith themerged images (merge is in yellow). Hoechst nuclear
staining is represented in blue. C, the fluorescence intensities of Myc-cyclin A2 in the nuclear (N, closed bar) and cytoplasmic (C, open bar) regions were
quantified using Image J software. The data shown are the means S.E. (n 5).
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PCTK3 wild type, whereas the phosphorylation of the S12A,
S66A, and S109A mutants was reduced as compared with that
of wild-type PCTK3 (Fig. 6D). These findings provided evi-
dence that PCTK3 is phosphorylated by PKA at three sites
(RRLS12, RRFS66, and RRAS109 in mouse) both in vitro and in
vivo.
PCTK3 Activity Is Regulated via Phosphorylation at Ser12 by
PKA—We then investigated the effects of PKA phosphoryla-
tion of PCTK3 on its kinase activity. PCTK3 activity was deter-
mined byGSTpulldown and in vitro kinase assays using RbC as
the substrate. Three phosphomimic PCTK3 mutants (PCTK3
S12D, S66D, and S109D), in which the PKA phosphorylation
sites were replaced by aspartic acid, were generated, and the
kinase activities of these phospho-mimic mutants were exam-
ined. As shown in Fig. 7A, the PCTK3 S12D mutant had rela-
tively high activity for Rb phosphorylation even in the absence
of cyclin A2. Furthermore, the catalytic activity of the cyclin
A2-S12D mutant complex was significantly increased (2-
fold) as compared with that of cyclin A2-wild-type PCTK3,
although the ability of S12Dmutant to bind to cyclin A was not
changed. By comparison, the PCTK3 S66D and S109Dmutants
had no effect on kinase activity. On the other hand, the activity
of the phospho-null mutant S12A was obviously decreased as
comparedwith that of wild-type PCTK3 (Fig. 7B), strongly sup-
porting that the phosphorylation at Ser12 influences the cata-
lytic activation. In addition, the kinase activity of the PCTK3
S12D mutant was compared with that of the cyclin A2-CDK2
complex. Although cyclin A2-wild-type PCTK3 activity was six
FIGURE 5. PCTK3 protects cyclin A2 against degradation in the cytoplasm. A, HEK293T cells were transfected with PCTK3 siRNA. The cell lysates were
subjected to immunoblotting (IB) with anti-PCTK3 and anti-cyclin A antibodies. Expression of -tubulin was used as a loading control. B, HEK293T cells were
cotransfected with GST or GST-PCTK3 together with FLAG-cyclin A2. After 24 h, cycloheximide (CHX) (5 g/ml) was added to the cell culture. Cells were
harvested at indicated times after cycloheximide treatment and FLAG-cyclin A2 protein levels were determined by immunoblotting (IB: anti-FLAG).
-Actin was used as a loading control (IB: anti--actin). FLAG-cyclin A2 protein levels were quantified by densitometric analysis and represented in a
graph. C, HEK293T cells were transfected with FLAG-PCTK3 and separated into nuclear and cytoplasmic fractions. The nuclear fractions were immuno-
precipitated (IP) using anti-CDK2 antibody, and the immunoprecipitates were used in an in vitro kinase assaywithMBP-Rb C as a substrate. Normal rabbit
IgG (IgG) was used as a control.
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times less than that of cyclin A2-CDK2, the cyclin A2-S12D
mutant had strong activity and reached a level comparable with
the kinase activity of cyclin A2-CDK2 (Fig. 7C).
We also determined whether endogenous PCTK3 was acti-
vated by PKA. First, to determine endogenous PCTK3 activity,
we immunoprecipitated PCTK3 from HEK293Tcells trans-
fected with negative control siRNA or PCTK3 siRNA and
determined in vitro kinase activity using Rb as the substrate. As
shown in Fig. 7D, significantly high Rb phosphorylation activity
was detected in immunoprecipitates fromcells transfectedwith
negative control siRNA as compared with those from cells
transfected with PCTK3 siRNA, suggesting that this activity
was dependent on endogenous PCTK3 activity. Therefore, we
assessed the effects of forskolin treatment on the kinase activity
of PCTK3. Rb phosphorylationwas significantly increased after
forskolin treatment. These data demonstrated that PCTK3 is
activated via phosphorylation at Ser12 by PKA.
Several members of the CDK family preferentially phos-
phorylate the canonical motif Ser/Thr-Pro-X-Lys/Arg/His
(where X represents any amino acid). Because PCTK3 phos-
phorylated Rb in vitro, we investigated whether Rb was phos-
phorylated by PCTK3 in vivo. HEK293T cells were trans-
fected with FLAG-tagged PCTK3 wild type or S12D mutant,
after which cell lysates were subjected to immunoblotting
using anti-phospho-Rb (Ser795). Both PCTK3 wild type and
S12D failed to phosphorylate endogenous Rb, although Rb
phosphorylation was detected in cyclin A2-CDK2-trans-
fected cells (Fig. 7E). This suggested that Rb is a poor sub-
strate for PCTK3 in vivo, possibly due to its different subcel-
lular localization.
Suppression of PCTK3 Induces Actin Cytoskeletal Changes
through Cofilin Phosphorylation—In a final set of experiments,
we explored possible physiological functions of PCTK3 using a
RNA interference approach. We noted that PCTK3 knock-
FIGURE 6. PCTK3 is phosphorylated by PKA in vitro and in vivo. A, endogenous PCTK3 is phosphorylated by PKA. HEK293T cells were treated with 10 M
forskolin for 30 min in the presence of 10% FBS. Cell lysates were immunoprecipitated (IP) with anti-PCTK3 antibody. Immunoprecipitates were analyzed by
immunoblot (IB) analysis using anti-phospho-RRX(S/T) or anti-PCTK3 antibodies. The bands of phosphorylated and total PCTK3 were indicated by arrows. B,
FLAG-PKA C, FLAG-PCTK3 wild type (WT), andmutants (S12A, S66A, S109, S449, S12A/S66A/S109A/S449A (4SA), and S12A/S66A/S109A (3SA)) were expressed
in COS-7 cells. Cell lysates were immunoprecipitated with anti-FLAG antibody. Immunoprecipitates were incubated with kinase buffer containing
[-32P]ATP. Equal amounts of cell lysates were analyzed by immunoblotting with anti-FLAG antibody. The graph indicates the phosphorylation rate of
PCTK3. The phosphorylation rate of wild-type PCTK3was taken as 100%. C, the double or triplemutants of PCTK3 (S12A/S66A, S12A/S109A, S66A/S109A,
and S12A/S66A/S109A (3SA)) were subjected to in vitro kinase assay using PKA. D, HeLa cells were transfected with FLAG-PCTK3 wild type (WT) and
mutants (S12A, S66A, S109A, and S12A/S66A/S109A (3SA)). After 24 h, transfected cells were treated with 10 M forskolin at 30 min. Cell extracts were
subjected to immunoprecipitated with anti-FLAG antibody (IP: anti-FLAG). Immunoprecipitates were subsequently analyzed by immunoblotting with
anti-phospho-RRX(S/T) or anti-FLAG antibody.
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down in HEK293T cells induced morphological changes, cell
spreading, and extensions (Fig. 8, A and B). To investigate
whether this is responsible for alteration of the actin cytoskel-
eton, we visualized F-actin by staining cells with phalloidin.
Control HEK293T cells exhibited a relatively weak cortical dis-
tribution of F-actin (Fig. 8B, upper panel). In PCTK3 knock-
FIGURE7.PCTK3activity is regulatedviaphosphorylationatSer12byPKA.A, COS-7cell lysatesexpressingGST,GST-PCTK3wild-type (WT), orGST-PCTK3mutants
(S12D, S66D, S109D, and S12D/S66D/S109D) and FLAG-cyclin A2 were used in a kinase assay using Rb as the substrate. The relative kinase activity of PCTK3 was
quantified by densitometric analysis. The activity of wild-type PCTK3 complexedwith FLAG-cyclin A2was taken as 1. Results are expressed as themeans S.E. from
three independent experiments. Statistical significancewas determinedby analysis of variance. ***, p 0.001. B, FLAG-PCTK3WT and S12D and S12Amutantswere
expressed with Myc-cyclin A2 in COS-7 cells. The cell lysates were immunoprecipitated (IP) with anti-FLAG antibody (IP: anti-FLAG), and an in vitro kinase assay was
performedusingMBP-RbCas the substrate.C, GST-PCTK3WT, S12Dmutant, andGST-CDK2wasexpressed inCOS-7 cellswithorwithout FLAG-cyclinA2. Theprotein
complexeswerepulleddownbyglutathione-Sepharosebeads, andan in vitrokinaseassaywasperformedusingMBP-RbCproteinas the substrate. Thegraphshows
theaverageof three independentexperiments.CBB,CoomassieBrilliantBlue.D, expressionofPCTK3 inHEK293TcellswasknockeddownbysiRNA.PCTK3knockdown
cells were treatedwith 10M forskolin for 30min inmedium containing 10%FBS. Cell lysateswere immunoprecipitatedwith anti-PCTK3 antibody. Immunoprecipi-
tateswere subjected to in vitrokinaseassayusingRbas the substrate. Theactivityof endogenousPCTK3 innegative control (NC) knockdowncellswas takenas100%.
Experimentswere performed three times independently. Results are expressed as themeans S.E. Statistical significancewas determinedby analysis of variance. *,
p 0.05. E, HEK293T cells were transfectedwith FLAG-PCTK3wild type and S12Dmutant, FLAG-CDK2, and FLAG-cyclin A2. After 24 h, cell extractswere analyzed by
immunoblottingwith anti-phospho-Rb (Ser795), anti-Rb, and anti-FLAG antibodies.
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down cells, lamellipodia extensions were induced, and F-actin
was concentrated at these lamellipodia. PCTK3 knockdown
also stimulated the appearance of stress fibers (Fig. 8B, lower
panel). Furthermore, the effects of PCTK3 overexpression on
actin filament dynamics were examined. Constitutively active
mutant of PCTK3 (PCTK3 S12D) suppressed formation of
actin stress fibers, whereas wild-type PCTK3 and S12Amutant
did not (Fig. 8C).
Actin filament dynamics are regulated by actin-depolymer-
izing factor/cofilin proteins, and cofilin is inactivated through
the phosphorylation at Ser3 (33, 34). Therefore, we investigated
the phosphorylation states of cofilin in PCTK3 knockdown
HEK293T cells by immunoblotting using anti-phospho-cofilin
(Ser3). As shown in Fig. 8D, cofilin phosphorylation in PCTK3
knockdown HEK293T cells was markedly increased as com-
pared with that in control cells. In contrast, overexpression of
PCTK3 S12D effectively suppressed cofilin phosphorylation
without affecting total cofilin protein levels, althoughwild-type
PCTK3 did not affect (Fig. 8E). The phospho-null S12Amutant
rather slightly increased. These data suggested that PCTK3was
involved in the actin cytoskeleton organization.
DISCUSSION
In this study we provided evidence for the activation mech-
anisms of PCTK3, the activity of which was regulated by two
pathways: binding to cyclin A2 and phosphorylation by PKA.
Cyclin A2 is widely expressed in various tissues and has been
proposed to regulate the transition from the S phase to the M
phase during the mitotic cell cycle. The canonical partners for
cyclin A2 are CDK1 and CDK2, and cyclin A2-CDK2 complex
has been generally used as a structural model of cyclin-CDK.
Crystal structure analysis revealed that cyclin A2 enhanced the
catalytic activity of CDK2 through rearrangement of its cata-
lytic core element, including the PSTAIRE helix (35). The
kinase domain of PCTK3 is highly conserved among isoforms
(80% identity) and has high sequence homology with that of
CDK2 (52% identity in humans) (5). Although the crystal struc-
ture of PCTK3 remains to be determined, that of PCTK1 is
available from the Protein Data Bank (PDB code 3MTL). By
comparison with the crystal structure of the cyclin A2-CDK2
complex, two amino acid residues of cyclin Y, Lys225 and
Glu253, have been identified as important residues for binding
FIGURE 8. Suppression of PCTK3 induces actin cytoskeletal changes through cofilin phosphorylation. A and B, HEK293T cells were transfected with
negative control siRNA or PCTK3 siRNA. After 48 h, cells were fixed and incubated with Alexa 555-conjugated phalloidin (B, red). Hoechst nuclear staining is
represented in blue. C, HEK293T cells were transfectedwith PCTK3 siRNA for 48 h and then transfectedwith FLAG-taggedmouse PCTK3wild type (WT) or S12D
or S12A mutants. After 24 h, cells were fixed and incubated with mouse anti-FLAG antibody. The primary antibody was visualized with Alexa Fluor 488-
conjugated anti-mouse IgG followedby confocalmicroscopy. Fluorescence for FLAG-PCTK3 (green) and F-actin (Alexa 555-conjugatedphalloidin staining, red)
are shown with merged images (merge is in yellow). Hoechst nuclear staining is represented in blue. D, cell lysates of PCTK3 knock-down HEK293T cells were
subjected to immunoblotting with anti-PCTK3, anti-cofilin, and anti-phospho-cofilin (Ser3) antibodies. Expression of -actin was used as a loading control. E,
HEK293T cells were transfectedwith FLAG-PCTK3 (WTor S12Dor S12Amutant). After 24 h, cell lysateswere subjected to immunoblotting using anti-phospho-
cofilin (Ser3), anti-cofilin, and anti-FLAG antibodies.
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to PCTK1 (24). This Lys-Glu pair is also found in other cyclins
and is likely to be a conserved structural motif in cyclin-CDK
complexes. This suggests that the Lys-Glu pair of cyclin A2 is
also likely to mediate the interaction with PCTK3. In addition,
we demonstrated that all three PCTK isoforms bound to cyclin
A2 at nearly equal affinity. These data suggested that PCTK3
may be associated with cyclin A2 through a common region of
PCTK isoforms, such as the PCTAIRE sequence. On the other
hand, the catalytic activities of PCTK1 and PCTK2 were not
affected by binding to cyclin A2. Furthermore, we found that
cyclin E1 did not affect the catalytic activity of PCTK3, although
it had a greater affinity for PCTK3 than cyclin A2. Several stud-
ies have showed that substrate recognition by CDKs is modu-
lated by their associations with different cyclins (36–39). For
example, although both cyclin A-CDK2 and cyclin E/CDK2
phosphorylate histone H1, only the cyclin A-CDK2 complex
phosphorylates lamin B in vitro (39). Furthermore, although
both cyclin A and cyclin E associate with CDK1, only cyclin A
activates CDK1 kinase activity, indicating that cyclin A and E
could modulate the substrate specificity of CDKs. These facts
raise the possibility that cyclin E1-PCTK3, cyclin A2-PCTK1,
and cyclin A2-PCTK2 complexes may have kinase activity
against other substrates but not Rb. On the other hand, cyclin E
inhibits the activity of CDK5 by competing with p35 for CDK5
binding (40). This suggests that cyclin E1 may inactivate
PCTK3 by dissociating cyclin A2 from PCTK3. To obtainmore
detailed information regarding the regulatory mechanism of
PCTK3 by cyclin A2 and cyclin E1, it will be necessary to per-
form crystal structure analysis. In an in vitro kinase assay, we
also found that cyclin A2-PCTK3 efficiently phosphorylates Rb
among Rb, MyBP, and histone H1. However, PCTK3, but not
CDK2, failed to phosphorylate endogenous Rb. Previous stud-
ies indicated that Rb regulates cell proliferation by controlling
the activity of various transcription factors in the nucleus (41,
42), suggesting that PCTK3 may not be able to make contact
with Rb because of the differences in their subcellular localiza-
tions. Taken together, PCTK3may be involved in other cellular
functions independent of the cell cycle via the phosphorylation
of its true substrates in the cytoplasm.
CyclinA2 lacks a nuclear localization signal and is dependent
on binding partners for its translocation between the nucleus
and the cytoplasm (30, 43). However, the precise translocation
mechanism for cyclin A2 remains obscure because CDK2 also
has no nuclear localization signal motif. Recently, SCAPERwas
identified and characterized as a substrate for cyclin A2-CDK2,
which is exclusively localized in the cytoplasm (14). Although
the function of SCAPER remains unknown, it was suggested
that SCAPER may act as a cytoplasmic pool for cyclin A2
and regulate cell cycle progression. On the other hand, we
found that PCTK3 bound to cyclin A2 in the cytoplasm and
promoted the translocation of cyclinA2 from the nucleus to the
cytoplasm. These results demonstrated that PCTK3 is a cyto-
plasmic binding partner of cyclinA2 and that cyclinA2 alters its
subcellular localization by binding to different partners.
The expression level of cyclinA2 is tightly controlled by tran-
scription and ubiquitin-mediated degradation. Cyclin A2 deg-
radation begins in early prometaphase and is completed by
metaphase. The major ubiquitin ligase required for mitosis is
APC/C (anaphase-promoting complex/cyclosome) (31).
Because the level of cyclin A2 protein was greatly reduced in
PCTK3 knockdown cells as comparedwith that in control cells,
we hypothesized that PCTK3 protects cyclin A2 from proteo-
lytic degradation. As expected, cycloheximide chase analysis
showed that cyclin A2 degradation is suppressed in the pres-
ence of PCTK3, whereas free cyclin A2 is readily degraded. A
previous study showed that cyclin E bound to CDK2 is also
protected from degradation by the proteasome (32). These
observations strongly support the physiological significance of
the association of between PCTK3 and cyclin A2.
Furthermore, PCTK3 was also activated by PKA via phos-
phorylation at Ser12, independently of its interaction with
cyclin A2. Endogenous PCTK3 in HEK293T cells was phos-
phorylated and activated by the PKA activator forskolin. In
addition, site-directed mutagenesis analysis revealed that PKA
phosphorylates Ser12, Ser66, and Ser109 of PCTK3. These results
indicate that PCTK3 is a bona fide substrate of PKA. Further-
more, the Rb phosphorylation activity of a phosphomimic
mutant of Ser12 (S12D) was comparable with the activity of
CDK2 in the presence of cyclin A2, suggesting that the com-
plete activation of PCTK3 is required for not only binding to
cyclinA2 but also for its phosphorylation at Ser12. Although the
S12D mutant caused an increase in PCTK3 activity, phospho-
mimicmutations of Ser66 and Ser109 (homologous to Ser119 and
Ser153 of PCTK1, respectively) had no effects on the Rb phos-
phorylation activity of PCTK3. Recently, Mikolcevic et al. (10)
reported that PKA plays an inhibitory role in the interaction
between PCTK1 and cyclin Y by phosphorylation at Ser153 of
PCTK1. On the other hand, phosphorylation at Ser153 of
PCTK1 creates the binding motif of 14-3-3 proteins and trans-
fers PCTK1 from the cell membrane to the cytoplasm. The
14-3-3 protein family includes seven members (, , , , 	, 
,
and ) in mammals, which are highly conserved and ubiqui-
tously expressed proteins (44). These 14-3-3 proteins can inter-
act with various proteins, usually by recognizing phosphoserine
or phosphothreonine motifs, and alter the activity, subcellular
localization, and interacting partners of their target proteins,
which in turnmodulate diverse biological processes. A previous
report showed that PCTK3 interacts with 14-3-3	 (45). Consis-
tent with this, we found that PCTK3 binds to several 14-3-3
isoforms.3 Therefore, PKA phosphorylation at Ser66 and Ser109
of PCTK3 may mediate the interactions with 14-3-3 proteins
and alter the subcellular localization of PCTK3.
Furthermore, PKA is involved in regulating of cell morphol-
ogy through phosphorylation of cytoskeletal proteins including
microtubules, intermediate filaments, and actin (46, 47). PKA
also regulates actin filament turnover by modulating the activ-
ity of LIM domain kinase 1 (LIMK1) (48). A recent study
reported that cyclin A2 plays a role in cytoskeletal reorganiza-
tion via its association with RhoA, a member of the small
GTPase family. Suppression of cyclin A2 by shRNA resulted in
an increase in cell size and cortical localization of F-actin inde-
pendent of the cell cycle, which led to increased cell migration
and invasion (15). Similar to the cyclin A2-deficient phenotype,
3 S. Matsuda, K. Kominato, and K. Yuasa, unpublished data.
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PCTK3 knockdown HEK293T cells also exhibited an increase
in cell size and F-actin accumulation at the edges of cell mem-
branes and increased cofilin phosphorylation. These data sug-
gest that PCTK3 activated through binding to cyclin A2, and
phosphorylation by PKA is involved in regulating cell motility
via reorganization of actin filaments. Although CDKs were
originally identified as enzymes that controlled cell cycle
events, some members of the CDK family are involved in other
cellular processes (49). For example, CDK5 is not considered to
play a significant role in cell cycle regulation; however, it has an
important function in the control of neurogenesis, including
neurite outgrowth, axon guidance, and cell migration. CDK5
activated by neuron-specific regulator p35 inhibits p21-acti-
vated kinase 1 (PAK1) activity through phosphorylation at
Thr212 (PVTPTRD, where T is Thr212) (50). PAK1, an effector
of Rac, has a pivotal role in cell morphology andmotility via the
LIM domain kinase/cofilin pathway (51). Phosphorylation of
PAK1 by p35/CDK5 is likely to be implicated in the dynamics of
the actin cytoskeleton reorganization. PCTK3 may also phos-
phorylate substrate proteins, such as PAK1, and control actin
dynamics.
In summary, we demonstrated that cyclin A2 is a specific
activator of PCTK3 and that phosphorylation at Ser12 of
PCTK3 significantly enhances its kinase activity in the absence
of cyclin A2. These findings shed light on the activation mech-
anism of not only PCTK3 but also other uncharacterizedmem-
bers of the CDK family, such as PCTK2. Further investigations
will be needed to clarify the physiological functions and patho-
logical roles of PCTK3.
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